
<!doctype html>
<html lang="en" class="no-js">
  <head>
    
      <meta charset="utf-8">
      <meta name="viewport" content="width=device-width,initial-scale=1">
      
      
      
        <link rel="canonical" href="https://vimbook.beauhilton.com/hematology-oncology/main/">
      
      <link rel="icon" href="../../images/vumc-favicon.png">
      <meta name="generator" content="mkdocs-1.3.0, mkdocs-material-8.3.7">
    
    
      
        <title>Main - VUMC IM Residency Handbook</title>
      
    
    
      <link rel="stylesheet" href="../../assets/stylesheets/main.4a0965b7.min.css">
      
        
        <link rel="stylesheet" href="../../assets/stylesheets/palette.cbb835fc.min.css">
        
      
      
    
    
    
      
        
        
        <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
        <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=IBM+Plex+Sans:300,300i,400,400i,700,700i%7CIBM+Plex+Mono:400,400i,700,700i&display=fallback">
        <style>:root{--md-text-font:"IBM Plex Sans";--md-code-font:"IBM Plex Mono"}</style>
      
    
    
      <link rel="stylesheet" href="../../css/print-site-enum-headings2.css">
    
      <link rel="stylesheet" href="../../css/print-site-enum-headings3.css">
    
      <link rel="stylesheet" href="../../css/print-site-enum-headings4.css">
    
      <link rel="stylesheet" href="../../css/print-site-enum-headings5.css">
    
      <link rel="stylesheet" href="../../css/print-site-enum-headings6.css">
    
      <link rel="stylesheet" href="../../css/print-site.css">
    
      <link rel="stylesheet" href="../../css/print-site-material.css">
    
      <link rel="stylesheet" href="../../stylesheets/extra.css">
    
    <script>__md_scope=new URL("../..",location),__md_get=(e,_=localStorage,t=__md_scope)=>JSON.parse(_.getItem(t.pathname+"."+e)),__md_set=(e,_,t=localStorage,a=__md_scope)=>{try{t.setItem(a.pathname+"."+e,JSON.stringify(_))}catch(e){}}</script>
    
      
  


  
  


  <script>window.ga=window.ga||function(){(ga.q=ga.q||[]).push(arguments)},ga.l=+new Date,ga("create","UA-105678972-1","auto"),ga("set","anonymizeIp",!0),ga("send","pageview"),document.addEventListener("DOMContentLoaded",function(){document.forms.search&&document.forms.search.query.addEventListener("blur",function(){var e;this.value&&(e=document.location.pathname,ga("send","pageview",e+"?q="+this.value))}),"undefined"!=typeof location$&&location$.subscribe(function(e){ga("send","pageview",e.pathname)})})</script>
  <script async src="https://www.google-analytics.com/analytics.js"></script>


    
    
 <link rel="apple-touch-icon" sizes="256x256" href="/images/apple-touch-icon.png">

  </head>
  
  
    
    
      
    
    
    
    
    <body dir="ltr" data-md-color-scheme="default" data-md-color-primary="black" data-md-color-accent="amber">
  
    
    
      <script>var palette=__md_get("__palette");if(palette&&"object"==typeof palette.color)for(var key of Object.keys(palette.color))document.body.setAttribute("data-md-color-"+key,palette.color[key])</script>
    
    <input class="md-toggle" data-md-toggle="drawer" type="checkbox" id="__drawer" autocomplete="off">
    <input class="md-toggle" data-md-toggle="search" type="checkbox" id="__search" autocomplete="off">
    <label class="md-overlay" for="__drawer"></label>
    <div data-md-component="skip">
      
    </div>
    <div data-md-component="announce">
      
    </div>
    
    
      

<header class="md-header" data-md-component="header">
  <nav class="md-header__inner md-grid" aria-label="Header">
    <a href="../.." title="VUMC IM Residency Handbook" class="md-header__button md-logo" aria-label="VUMC IM Residency Handbook" data-md-component="logo">
      
  <img src="../../images/vumc-favicon.png" alt="logo">

    </a>
    <label class="md-header__button md-icon" for="__drawer">
      <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M3 6h18v2H3V6m0 5h18v2H3v-2m0 5h18v2H3v-2Z"/></svg>
    </label>
    <div class="md-header__title" data-md-component="header-title">
      <div class="md-header__ellipsis">
        <div class="md-header__topic">
          <span class="md-ellipsis">
            VUMC IM Residency Handbook
          </span>
        </div>
        <div class="md-header__topic" data-md-component="header-topic">
          <span class="md-ellipsis">
            
              Main
            
          </span>
        </div>
      </div>
    </div>
    
      <form class="md-header__option" data-md-component="palette">
        
          
          
          <input class="md-option" data-md-color-media="" data-md-color-scheme="default" data-md-color-primary="black" data-md-color-accent="amber"  aria-label="Switch to dark mode"  type="radio" name="__palette" id="__palette_1">
          
            <label class="md-header__button md-icon" title="Switch to dark mode" for="__palette_2" hidden>
              <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M17 6H7c-3.31 0-6 2.69-6 6s2.69 6 6 6h10c3.31 0 6-2.69 6-6s-2.69-6-6-6zm0 10H7c-2.21 0-4-1.79-4-4s1.79-4 4-4h10c2.21 0 4 1.79 4 4s-1.79 4-4 4zM7 9c-1.66 0-3 1.34-3 3s1.34 3 3 3 3-1.34 3-3-1.34-3-3-3z"/></svg>
            </label>
          
        
          
          
          <input class="md-option" data-md-color-media="" data-md-color-scheme="slate" data-md-color-primary="black" data-md-color-accent="amber"  aria-label="Switch to light mode"  type="radio" name="__palette" id="__palette_2">
          
            <label class="md-header__button md-icon" title="Switch to light mode" for="__palette_1" hidden>
              <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M17 7H7a5 5 0 0 0-5 5 5 5 0 0 0 5 5h10a5 5 0 0 0 5-5 5 5 0 0 0-5-5m0 8a3 3 0 0 1-3-3 3 3 0 0 1 3-3 3 3 0 0 1 3 3 3 3 0 0 1-3 3Z"/></svg>
            </label>
          
        
      </form>
    
    
    
      <label class="md-header__button md-icon" for="__search">
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M9.5 3A6.5 6.5 0 0 1 16 9.5c0 1.61-.59 3.09-1.56 4.23l.27.27h.79l5 5-1.5 1.5-5-5v-.79l-.27-.27A6.516 6.516 0 0 1 9.5 16 6.5 6.5 0 0 1 3 9.5 6.5 6.5 0 0 1 9.5 3m0 2C7 5 5 7 5 9.5S7 14 9.5 14 14 12 14 9.5 12 5 9.5 5Z"/></svg>
      </label>
      <div class="md-search" data-md-component="search" role="dialog">
  <label class="md-search__overlay" for="__search"></label>
  <div class="md-search__inner" role="search">
    <form class="md-search__form" name="search">
      <input type="text" class="md-search__input" name="query" aria-label="Search" placeholder="Search" autocapitalize="off" autocorrect="off" autocomplete="off" spellcheck="false" data-md-component="search-query" required>
      <label class="md-search__icon md-icon" for="__search">
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M9.5 3A6.5 6.5 0 0 1 16 9.5c0 1.61-.59 3.09-1.56 4.23l.27.27h.79l5 5-1.5 1.5-5-5v-.79l-.27-.27A6.516 6.516 0 0 1 9.5 16 6.5 6.5 0 0 1 3 9.5 6.5 6.5 0 0 1 9.5 3m0 2C7 5 5 7 5 9.5S7 14 9.5 14 14 12 14 9.5 12 5 9.5 5Z"/></svg>
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M20 11v2H8l5.5 5.5-1.42 1.42L4.16 12l7.92-7.92L13.5 5.5 8 11h12Z"/></svg>
      </label>
      <nav class="md-search__options" aria-label="Search">
        
          <a href="javascript:void(0)" class="md-search__icon md-icon" aria-label="Share" data-clipboard data-clipboard-text="" data-md-component="search-share" tabindex="-1">
            <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M18 16.08c-.76 0-1.44.3-1.96.77L8.91 12.7c.05-.23.09-.46.09-.7 0-.24-.04-.47-.09-.7l7.05-4.11c.54.5 1.25.81 2.04.81a3 3 0 0 0 3-3 3 3 0 0 0-3-3 3 3 0 0 0-3 3c0 .24.04.47.09.7L8.04 9.81C7.5 9.31 6.79 9 6 9a3 3 0 0 0-3 3 3 3 0 0 0 3 3c.79 0 1.5-.31 2.04-.81l7.12 4.15c-.05.21-.08.43-.08.66 0 1.61 1.31 2.91 2.92 2.91 1.61 0 2.92-1.3 2.92-2.91A2.92 2.92 0 0 0 18 16.08Z"/></svg>
          </a>
        
        <button type="reset" class="md-search__icon md-icon" aria-label="Clear" tabindex="-1">
          <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M19 6.41 17.59 5 12 10.59 6.41 5 5 6.41 10.59 12 5 17.59 6.41 19 12 13.41 17.59 19 19 17.59 13.41 12 19 6.41Z"/></svg>
        </button>
      </nav>
      
        <div class="md-search__suggest" data-md-component="search-suggest"></div>
      
    </form>
    <div class="md-search__output">
      <div class="md-search__scrollwrap" data-md-scrollfix>
        <div class="md-search-result" data-md-component="search-result">
          <div class="md-search-result__meta">
            Initializing search
          </div>
          <ol class="md-search-result__list"></ol>
        </div>
      </div>
    </div>
  </div>
</div>
    
    
      <div class="md-header__source">
        <a href="https://github.com/vanderbilt-internal-medicine/vimbook" title="Go to repository" class="md-source" data-md-component="source">
  <div class="md-source__icon md-icon">
    
    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 448 512"><!--! Font Awesome Free 6.1.1 by @fontawesome - https://fontawesome.com License - https://fontawesome.com/license/free (Icons: CC BY 4.0, Fonts: SIL OFL 1.1, Code: MIT License) Copyright 2022 Fonticons, Inc.--><path d="M439.55 236.05 244 40.45a28.87 28.87 0 0 0-40.81 0l-40.66 40.63 51.52 51.52c27.06-9.14 52.68 16.77 43.39 43.68l49.66 49.66c34.23-11.8 61.18 31 35.47 56.69-26.49 26.49-70.21-2.87-56-37.34L240.22 199v121.85c25.3 12.54 22.26 41.85 9.08 55a34.34 34.34 0 0 1-48.55 0c-17.57-17.6-11.07-46.91 11.25-56v-123c-20.8-8.51-24.6-30.74-18.64-45L142.57 101 8.45 235.14a28.86 28.86 0 0 0 0 40.81l195.61 195.6a28.86 28.86 0 0 0 40.8 0l194.69-194.69a28.86 28.86 0 0 0 0-40.81z"/></svg>
  </div>
  <div class="md-source__repository">
    GitHub
  </div>
</a>
      </div>
    
  </nav>
  
</header>
    
    <div class="md-container" data-md-component="container">
      
      
        
          
        
      
      <main class="md-main" data-md-component="main">
        <div class="md-main__inner md-grid">
          
            
              
              <div class="md-sidebar md-sidebar--primary" data-md-component="sidebar" data-md-type="navigation" >
                <div class="md-sidebar__scrollwrap">
                  <div class="md-sidebar__inner">
                    


<nav class="md-nav md-nav--primary" aria-label="Navigation" data-md-level="0">
  <label class="md-nav__title" for="__drawer">
    <a href="../.." title="VUMC IM Residency Handbook" class="md-nav__button md-logo" aria-label="VUMC IM Residency Handbook" data-md-component="logo">
      
  <img src="../../images/vumc-favicon.png" alt="logo">

    </a>
    VUMC IM Residency Handbook
  </label>
  
    <div class="md-nav__source">
      <a href="https://github.com/vanderbilt-internal-medicine/vimbook" title="Go to repository" class="md-source" data-md-component="source">
  <div class="md-source__icon md-icon">
    
    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 448 512"><!--! Font Awesome Free 6.1.1 by @fontawesome - https://fontawesome.com License - https://fontawesome.com/license/free (Icons: CC BY 4.0, Fonts: SIL OFL 1.1, Code: MIT License) Copyright 2022 Fonticons, Inc.--><path d="M439.55 236.05 244 40.45a28.87 28.87 0 0 0-40.81 0l-40.66 40.63 51.52 51.52c27.06-9.14 52.68 16.77 43.39 43.68l49.66 49.66c34.23-11.8 61.18 31 35.47 56.69-26.49 26.49-70.21-2.87-56-37.34L240.22 199v121.85c25.3 12.54 22.26 41.85 9.08 55a34.34 34.34 0 0 1-48.55 0c-17.57-17.6-11.07-46.91 11.25-56v-123c-20.8-8.51-24.6-30.74-18.64-45L142.57 101 8.45 235.14a28.86 28.86 0 0 0 0 40.81l195.61 195.6a28.86 28.86 0 0 0 40.8 0l194.69-194.69a28.86 28.86 0 0 0 0-40.81z"/></svg>
  </div>
  <div class="md-source__repository">
    GitHub
  </div>
</a>
    </div>
  
  <ul class="md-nav__list" data-md-scrollfix>
    
      
      
      

  
  
  
    <li class="md-nav__item">
      <a href="../.." class="md-nav__link">
        Home
      </a>
    </li>
  

    
      
      
      

  
  
  
    
    <li class="md-nav__item md-nav__item--nested">
      
      
        <input class="md-nav__toggle md-toggle" data-md-toggle="__nav_2" type="checkbox" id="__nav_2" >
      
      
      
      
        <label class="md-nav__link" for="__nav_2">
          Introduction
          <span class="md-nav__icon md-icon"></span>
        </label>
      
      <nav class="md-nav" aria-label="Introduction" data-md-level="1">
        <label class="md-nav__title" for="__nav_2">
          <span class="md-nav__icon md-icon"></span>
          Introduction
        </label>
        <ul class="md-nav__list" data-md-scrollfix>
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../introduction/introduction-acknowledgements/" class="md-nav__link">
        Acknowledgements
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../introduction/introduction-authors-editors-reviewers/" class="md-nav__link">
        Editors, Authors, and Reviewers
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../introduction/introduction-disclaimers/" class="md-nav__link">
        Disclaimers
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../introduction/introduction-rationale/" class="md-nav__link">
        Rationale
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../introduction/introduction-web-app-setup/" class="md-nav__link">
        Web App Setup
      </a>
    </li>
  

            
          
        </ul>
      </nav>
    </li>
  

    
      
      
      

  
  
  
    
    <li class="md-nav__item md-nav__item--nested">
      
      
        <input class="md-nav__toggle md-toggle" data-md-toggle="__nav_3" type="checkbox" id="__nav_3" >
      
      
      
      
        <label class="md-nav__link" for="__nav_3">
          Cardiology
          <span class="md-nav__icon md-icon"></span>
        </label>
      
      <nav class="md-nav" aria-label="Cardiology" data-md-level="1">
        <label class="md-nav__title" for="__nav_3">
          <span class="md-nav__icon md-icon"></span>
          Cardiology
        </label>
        <ul class="md-nav__list" data-md-scrollfix>
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../cardiology/cardiology-acs/" class="md-nav__link">
        Acute Coronary Syndromes
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../cardiology/cardiology-arrhythmias/" class="md-nav__link">
        Arrhythmias
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../cardiology/cardiology-atrial-fibrillation-and-flutter/" class="md-nav__link">
        Atrial Fibrillation & Flutter
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../cardiology/cardiology-autonomics-and-orthostatics/" class="md-nav__link">
        Autonomics and Orthostatic Hypotension
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../cardiology/cardiology-bedside-echocardiography/" class="md-nav__link">
        Bedside Echocardiography
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../cardiology/cardiology-cardiac-devices/" class="md-nav__link">
        Cardiac Devices
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../cardiology/cardiology-chest-pain/" class="md-nav__link">
        Chest Pain
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../cardiology/cardiology-chf/" class="md-nav__link">
        Heart Failure
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../cardiology/cardiology-ekg/" class="md-nav__link">
        Approach to the ECG
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../cardiology/cardiology-inpatient-hypertension/" class="md-nav__link">
        Inpatient Hypertension
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../cardiology/cardiology-pe/" class="md-nav__link">
        Pulmonary Embolism
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../cardiology/cardiology-rhc/" class="md-nav__link">
        Right Heart Catheterization
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../cardiology/cardiology-shock/" class="md-nav__link">
        Cardiogenic Shock
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../cardiology/cardiology-syncope/" class="md-nav__link">
        Syncope
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../cardiology/cardiology-valvular-heart-disease/" class="md-nav__link">
        Valvular Heart Disease
      </a>
    </li>
  

            
          
        </ul>
      </nav>
    </li>
  

    
      
      
      

  
  
  
    
    <li class="md-nav__item md-nav__item--nested">
      
      
        <input class="md-nav__toggle md-toggle" data-md-toggle="__nav_4" type="checkbox" id="__nav_4" >
      
      
      
      
        <label class="md-nav__link" for="__nav_4">
          Critical care
          <span class="md-nav__icon md-icon"></span>
        </label>
      
      <nav class="md-nav" aria-label="Critical care" data-md-level="1">
        <label class="md-nav__title" for="__nav_4">
          <span class="md-nav__icon md-icon"></span>
          Critical care
        </label>
        <ul class="md-nav__list" data-md-scrollfix>
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../critical-care/critical-care-abcdef-a2f-bundle/" class="md-nav__link">
        ABCDEF (A2F) Bundle
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../critical-care/critical-care-ards/" class="md-nav__link">
        Acute Respiratory Distress Syndrome (ARDS)
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../critical-care/critical-care-brain-death/" class="md-nav__link">
        Brain Death
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../critical-care/critical-care-codes/" class="md-nav__link">
        Running Codes
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../critical-care/critical-care-drips/" class="md-nav__link">
        MICU/CCU Drips
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../critical-care/critical-care-intubation-extubation/" class="md-nav__link">
        Intubation and Extubation
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../critical-care/critical-care-modes-oxygen-delivery/" class="md-nav__link">
        Modes of Oxygen Delivery
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../critical-care/critical-care-refractory-hypercapnia/" class="md-nav__link">
        Refractory Hypercapnia
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../critical-care/critical-care-refractory-hypoxemia/" class="md-nav__link">
        Refractory Hypoxemia
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../critical-care/critical-care-sepsis/" class="md-nav__link">
        Sepsis
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../critical-care/critical-care-shock/" class="md-nav__link">
        Management of Shock
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../critical-care/critical-care-temperature-abnormalities/" class="md-nav__link">
        Temperature Abnormalities
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../critical-care/critical-care-tracheostomy/" class="md-nav__link">
        Tracheostomy
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../critical-care/critical-care-ultrasound/" class="md-nav__link">
        Ultrasound in Critical Care
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../critical-care/critical-care-vent-settings/" class="md-nav__link">
        Introduction to Vent Management
      </a>
    </li>
  

            
          
        </ul>
      </nav>
    </li>
  

    
      
      
      

  
  
  
    
    <li class="md-nav__item md-nav__item--nested">
      
      
        <input class="md-nav__toggle md-toggle" data-md-toggle="__nav_5" type="checkbox" id="__nav_5" >
      
      
      
      
        <label class="md-nav__link" for="__nav_5">
          Demo
          <span class="md-nav__icon md-icon"></span>
        </label>
      
      <nav class="md-nav" aria-label="Demo" data-md-level="1">
        <label class="md-nav__title" for="__nav_5">
          <span class="md-nav__icon md-icon"></span>
          Demo
        </label>
        <ul class="md-nav__list" data-md-scrollfix>
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../demo/demo-lights/" class="md-nav__link">
        Pleural Effusions
      </a>
    </li>
  

            
          
        </ul>
      </nav>
    </li>
  

    
      
      
      

  
  
  
    
    <li class="md-nav__item md-nav__item--nested">
      
      
        <input class="md-nav__toggle md-toggle" data-md-toggle="__nav_6" type="checkbox" id="__nav_6" >
      
      
      
      
        <label class="md-nav__link" for="__nav_6">
          Endocrinology
          <span class="md-nav__icon md-icon"></span>
        </label>
      
      <nav class="md-nav" aria-label="Endocrinology" data-md-level="1">
        <label class="md-nav__title" for="__nav_6">
          <span class="md-nav__icon md-icon"></span>
          Endocrinology
        </label>
        <ul class="md-nav__list" data-md-scrollfix>
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../endocrinology/endocrinology-adrenal-incidentalomas/" class="md-nav__link">
        Adrenal Incidentalomas
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../endocrinology/endocrinology-adrenal-insufficiency/" class="md-nav__link">
        Adrenal Insufficiency
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../endocrinology/endocrinology-diabetes-inpatient-management/" class="md-nav__link">
        Inpatient Diabetes Mellitus (DM)
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../endocrinology/endocrinology-dka/" class="md-nav__link">
        Diabetic Ketoacidosis (DKA)
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../endocrinology/endocrinology-hyperthyroidism/" class="md-nav__link">
        Hyperthyroidism
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../endocrinology/endocrinology-hypoglycemia/" class="md-nav__link">
        Hypoglycemia
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../endocrinology/endocrinology-hypothyroidism/" class="md-nav__link">
        Hypothyroidism
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../endocrinology/endocrinology-severe-hypertriglyceridemia/" class="md-nav__link">
        Severe Hypertriglyceridemia (HTG)
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../endocrinology/endocrinology-steroid-conversions/" class="md-nav__link">
        Steroid Conversions
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../endocrinology/endocrinology-stress-dose-steroids/" class="md-nav__link">
        Stress Dose Steroids
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../endocrinology/endocrinology-thyroid-nodules/" class="md-nav__link">
        Thyroid Nodules
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../endocrinology/endocrinology-thyroid-storm/" class="md-nav__link">
        Thyroid Storm
      </a>
    </li>
  

            
          
        </ul>
      </nav>
    </li>
  

    
      
      
      

  
  
  
    
    <li class="md-nav__item md-nav__item--nested">
      
      
        <input class="md-nav__toggle md-toggle" data-md-toggle="__nav_7" type="checkbox" id="__nav_7" >
      
      
      
      
        <label class="md-nav__link" for="__nav_7">
          Gastroenterology
          <span class="md-nav__icon md-icon"></span>
        </label>
      
      <nav class="md-nav" aria-label="Gastroenterology" data-md-level="1">
        <label class="md-nav__title" for="__nav_7">
          <span class="md-nav__icon md-icon"></span>
          Gastroenterology
        </label>
        <ul class="md-nav__list" data-md-scrollfix>
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../gastroenterology/gastroenterology-acute-abdominal-pain/" class="md-nav__link">
        Acute Abdominal Pain
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../gastroenterology/gastroenterology-acute-diverticulitis/" class="md-nav__link">
        Acute Diverticulitis
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../gastroenterology/gastroenterology-acute-pancreatitis/" class="md-nav__link">
        Acute Pancreatitis
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../gastroenterology/gastroenterology-biliary-disease/" class="md-nav__link">
        Biliary Disease
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../gastroenterology/gastroenterology-c-diff/" class="md-nav__link">
        Clostridioides Difficile Infections
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../gastroenterology/gastroenterology-chronic-pancreatitis/" class="md-nav__link">
        Chronic Pancreatitis
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../gastroenterology/gastroenterology-constipation/" class="md-nav__link">
        Constipation
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../gastroenterology/gastroenterology-diarrhea/" class="md-nav__link">
        Diarrhea
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../gastroenterology/gastroenterology-esophageal-disorders/" class="md-nav__link">
        Esophageal Disorders
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../gastroenterology/gastroenterology-gastroparesis/" class="md-nav__link">
        Gastroparesis
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../gastroenterology/gastroenterology-gi-bleeding/" class="md-nav__link">
        GI Bleeding
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../gastroenterology/gastroenterology-gi-covid/" class="md-nav__link">
        GI Manifestations of COVID
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../gastroenterology/gastroenterology-ibs/" class="md-nav__link">
        Irritable Bowel Syndrome
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../gastroenterology/gastroenterology-inflammatory-bowel-disease/" class="md-nav__link">
        Inflammatory Bowel Disease
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../gastroenterology/gastroenterology-intestinal-ischemia/" class="md-nav__link">
        Intestinal Ischemia
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../gastroenterology/gastroenterology-nausea-vomiting/" class="md-nav__link">
        Nausea & Vomiting
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../gastroenterology/gastroenterology-peptic-ulcer-disease/" class="md-nav__link">
        Peptic Ulcer Disease
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../gastroenterology/gastroenterology-small-bowel-obstruction/" class="md-nav__link">
        Small Bowel Obstruction (SBO)
      </a>
    </li>
  

            
          
        </ul>
      </nav>
    </li>
  

    
      
      
      

  
  
  
    
    <li class="md-nav__item md-nav__item--nested">
      
      
        <input class="md-nav__toggle md-toggle" data-md-toggle="__nav_8" type="checkbox" id="__nav_8" >
      
      
      
      
        <label class="md-nav__link" for="__nav_8">
          Geriatrics
          <span class="md-nav__icon md-icon"></span>
        </label>
      
      <nav class="md-nav" aria-label="Geriatrics" data-md-level="1">
        <label class="md-nav__title" for="__nav_8">
          <span class="md-nav__icon md-icon"></span>
          Geriatrics
        </label>
        <ul class="md-nav__list" data-md-scrollfix>
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../geriatrics/geriatrics-dementia/" class="md-nav__link">
        Dementia
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../geriatrics/geriatrics-falls/" class="md-nav__link">
        Falls
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../geriatrics/geriatrics-frailty/" class="md-nav__link">
        Frailty
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../geriatrics/geriatrics-functional-status/" class="md-nav__link">
        Functional Status
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../geriatrics/geriatrics-malnutrition/" class="md-nav__link">
        Malnutrition
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../geriatrics/geriatrics-medication-management/" class="md-nav__link">
        Medication Management
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../geriatrics/geriatrics-overview/" class="md-nav__link">
        Geriatrics Overview
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../geriatrics/geriatrics-urinary-incontinence-and-foley-catheter/" class="md-nav__link">
        Urinary Incontinence and Foley Catheters
      </a>
    </li>
  

            
          
        </ul>
      </nav>
    </li>
  

    
      
      
      

  
  
    
  
  
    
    <li class="md-nav__item md-nav__item--active md-nav__item--nested">
      
      
        <input class="md-nav__toggle md-toggle" data-md-toggle="__nav_9" type="checkbox" id="__nav_9" checked>
      
      
      
      
        <label class="md-nav__link" for="__nav_9">
          Hematology oncology
          <span class="md-nav__icon md-icon"></span>
        </label>
      
      <nav class="md-nav" aria-label="Hematology oncology" data-md-level="1">
        <label class="md-nav__title" for="__nav_9">
          <span class="md-nav__icon md-icon"></span>
          Hematology oncology
        </label>
        <ul class="md-nav__list" data-md-scrollfix>
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hematologyoncology-anemia/" class="md-nav__link">
        Anemia
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hematologyoncology-anticoagulation/" class="md-nav__link">
        Anticoagulation
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hematologyoncology-bone-marrow-transplant/" class="md-nav__link">
        Bone Marrow Transplant
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hematologyoncology-chemotherapy-toxicity/" class="md-nav__link">
        Chemotherapy Toxicity
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hematologyoncology-coagulopathies/" class="md-nav__link">
        Coagulopathies
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hematologyoncology-dic/" class="md-nav__link">
        DIC
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hematologyoncology-dvts/" class="md-nav__link">
        DVTs
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hematologyoncology-hypercoagulable-states/" class="md-nav__link">
        Hypercoagulable States
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hematologyoncology-leukemia/" class="md-nav__link">
        Leukemia
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hematologyoncology-lymphoma/" class="md-nav__link">
        Lymphoma
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hematologyoncology-medical-oncology-resources/" class="md-nav__link">
        Medical Oncology Resources
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hematologyoncology-myelodysplastic-syndromes/" class="md-nav__link">
        Myelodysplastic Syndromes
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hematologyoncology-myeloproliferative-neoplasms/" class="md-nav__link">
        Myeloproliferative Neoplasms
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hematologyoncology-neutropenia-and-neutropenic-fever/" class="md-nav__link">
        Neutropenia and Neutropenic Fever
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hematologyoncology-oncologic-emergencies/" class="md-nav__link">
        Oncologic Emergencies
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hematologyoncology-paraneoplastic-syndromes/" class="md-nav__link">
        Paraneoplastic Syndromes
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hematologyoncology-plasma-cell-dyscrasias/" class="md-nav__link">
        Plasma Cell Dyscrasias
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hematologyoncology-sickle-cell-crisis/" class="md-nav__link">
        Sickle Cell Crisis
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hematologyoncology-thrombocytopenia/" class="md-nav__link">
        Thrombocytopenia
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hematologyoncology-transfusion-medicine/" class="md-nav__link">
        Transfusion Medicine
      </a>
    </li>
  

            
          
            
              
  
  
    
  
  
    <li class="md-nav__item md-nav__item--active">
      
      <input class="md-nav__toggle md-toggle" data-md-toggle="toc" type="checkbox" id="__toc">
      
      
      
      <a href="./" class="md-nav__link md-nav__link--active">
        Main
      </a>
      
    </li>
  

            
          
        </ul>
      </nav>
    </li>
  

    
      
      
      

  
  
  
    
    <li class="md-nav__item md-nav__item--nested">
      
      
        <input class="md-nav__toggle md-toggle" data-md-toggle="__nav_10" type="checkbox" id="__nav_10" >
      
      
      
      
        <label class="md-nav__link" for="__nav_10">
          Hepatology
          <span class="md-nav__icon md-icon"></span>
        </label>
      
      <nav class="md-nav" aria-label="Hepatology" data-md-level="1">
        <label class="md-nav__title" for="__nav_10">
          <span class="md-nav__icon md-icon"></span>
          Hepatology
        </label>
        <ul class="md-nav__list" data-md-scrollfix>
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../hepatology/hepatology-acute-liver-failure/" class="md-nav__link">
        Acute Liver Injury and Failure
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../hepatology/hepatology-alcoholic-hepatitis/" class="md-nav__link">
        Alcoholic Hepatitis
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../hepatology/hepatology-ascites/" class="md-nav__link">
        Ascites and Hepatic Hydrothorax
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../hepatology/hepatology-cirrhosis/" class="md-nav__link">
        Cirrhosis Overview
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../hepatology/hepatology-coagulopathy/" class="md-nav__link">
        Coagulopathy in Cirrhosis
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../hepatology/hepatology-hepatic-encephalopathy/" class="md-nav__link">
        Hepatic Encephalopathy (HE)
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../hepatology/hepatology-hepatocellular-carcinoma/" class="md-nav__link">
        Hepatocellular Carcinoma (HCC)
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../hepatology/hepatology-hepatorenal-syndrome/" class="md-nav__link">
        Hepatorenal Syndrome
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../hepatology/hepatology-hyponatremia-cirrhosis/" class="md-nav__link">
        Hyponatremia in Cirrhosis
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../hepatology/hepatology-liver-transplantation/" class="md-nav__link">
        Liver Transplant (LT) Workup
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../hepatology/hepatology-nash-and-nafld/" class="md-nav__link">
        NASH and NAFLD
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../hepatology/hepatology-portal-vein-thrombosis/" class="md-nav__link">
        Portal Vein Thrombosis (PVT)
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../hepatology/hepatology-sbp/" class="md-nav__link">
        Spontaneous Bacterial Peritonitis (SBP)
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../hepatology/hepatology-tips/" class="md-nav__link">
        Transjugular Intrahepatic Portosystemic Shunt (TIPS)
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../hepatology/hepatology-upper-gi-bleed-cirrhosis/" class="md-nav__link">
        Gastroesophageal Varices and Hemorrhage
      </a>
    </li>
  

            
          
        </ul>
      </nav>
    </li>
  

    
      
      
      

  
  
  
    
    <li class="md-nav__item md-nav__item--nested">
      
      
        <input class="md-nav__toggle md-toggle" data-md-toggle="__nav_11" type="checkbox" id="__nav_11" >
      
      
      
      
        <label class="md-nav__link" for="__nav_11">
          Hospital medicine
          <span class="md-nav__icon md-icon"></span>
        </label>
      
      <nav class="md-nav" aria-label="Hospital medicine" data-md-level="1">
        <label class="md-nav__title" for="__nav_11">
          <span class="md-nav__icon md-icon"></span>
          Hospital medicine
        </label>
        <ul class="md-nav__list" data-md-scrollfix>
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../hospital-medicine/hospital-medicine-enteral-nutrition/" class="md-nav__link">
        Enteral Nutrition
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../hospital-medicine/hospital-medicine-guidelines-pregnant-patients/" class="md-nav__link">
        Guidelines for Pregnant Patients
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../hospital-medicine/hospital-medicine-lines-and-catheters/" class="md-nav__link">
        Lines and Catheters
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../hospital-medicine/hospital-medicine-telemetry/" class="md-nav__link">
        Telemetry
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../hospital-medicine/hospital-medicine-transitions-of-care/" class="md-nav__link">
        Transitions of Care: Tips for Safe Discharges
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../hospital-medicine/hospital-medicine-wounds/" class="md-nav__link">
        Wounds − Adapted from Dr. Duggan’s Geriatrics Guide
      </a>
    </li>
  

            
          
        </ul>
      </nav>
    </li>
  

    
      
      
      

  
  
  
    
    <li class="md-nav__item md-nav__item--nested">
      
      
        <input class="md-nav__toggle md-toggle" data-md-toggle="__nav_12" type="checkbox" id="__nav_12" >
      
      
      
      
        <label class="md-nav__link" for="__nav_12">
          Infectious diseases
          <span class="md-nav__icon md-icon"></span>
        </label>
      
      <nav class="md-nav" aria-label="Infectious diseases" data-md-level="1">
        <label class="md-nav__title" for="__nav_12">
          <span class="md-nav__icon md-icon"></span>
          Infectious diseases
        </label>
        <ul class="md-nav__list" data-md-scrollfix>
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../infectious-diseases/infectious-disease-overview-art/" class="md-nav__link">
        Overview of Antiretroviral Therapy
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../infectious-diseases/infectious-disease-sexually-transmitted-diseases/" class="md-nav__link">
        Sexually Transmitted Infections
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../infectious-diseases/infectious-diseases-aids-defining-conditions/" class="md-nav__link">
        AIDS Defining Clinical Conditions
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../infectious-diseases/infectious-diseases-antimicrobial-prophylaxis/" class="md-nav__link">
        Antimicrobial Prophylaxis per CD4 Counts
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../infectious-diseases/infectious-diseases-bacteremia/" class="md-nav__link">
        Bacteremia: Interpreting GenMark ePlex® Results – VASP
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../infectious-diseases/infectious-diseases-cns-infection/" class="md-nav__link">
        Central Nervous System Infection – VASP
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../infectious-diseases/infectious-diseases-diabetic-foot-infection/" class="md-nav__link">
        Diabetic Foot Infection – VASP
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../infectious-diseases/infectious-diseases-endocarditis/" class="md-nav__link">
        Endocarditis
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../infectious-diseases/infectious-diseases-fungal-infections/" class="md-nav__link">
        Fungal Infections
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../infectious-diseases/infectious-diseases-general-tips/" class="md-nav__link">
        General Tips
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../infectious-diseases/infectious-diseases-gu-infection/" class="md-nav__link">
        Genitourinary Infection – VASP
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../infectious-diseases/infectious-diseases-hiv-art-general-concepts/" class="md-nav__link">
        HIV/AIDS and ART
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../infectious-diseases/infectious-diseases-inpatient-covid19/" class="md-nav__link">
        Inpatient COVID-19 Management
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../infectious-diseases/infectious-diseases-orthopedic-infection/" class="md-nav__link">
        Joint Infections and Osteomyelitis – VASP
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../infectious-diseases/infectious-diseases-pulmonary-infections/" class="md-nav__link">
        Pulmonary Infections
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../infectious-diseases/infectious-diseases-ssti/" class="md-nav__link">
        Skin and Soft Tissue Infection (SSTI) - VASP
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../infectious-diseases/main/" class="md-nav__link">
        Main
      </a>
    </li>
  

            
          
        </ul>
      </nav>
    </li>
  

    
      
      
      

  
  
  
    
    <li class="md-nav__item md-nav__item--nested">
      
      
        <input class="md-nav__toggle md-toggle" data-md-toggle="__nav_13" type="checkbox" id="__nav_13" >
      
      
      
      
        <label class="md-nav__link" for="__nav_13">
          Nephrology
          <span class="md-nav__icon md-icon"></span>
        </label>
      
      <nav class="md-nav" aria-label="Nephrology" data-md-level="1">
        <label class="md-nav__title" for="__nav_13">
          <span class="md-nav__icon md-icon"></span>
          Nephrology
        </label>
        <ul class="md-nav__list" data-md-scrollfix>
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../nephrology/main/" class="md-nav__link">
        Main
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../nephrology/nephrology-acid-base/" class="md-nav__link">
        Acid-Base
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../nephrology/nephrology-acute-rejection/" class="md-nav__link">
        Acute Rejection
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../nephrology/nephrology-aki/" class="md-nav__link">
        Acute Kidney Injury (AKI)
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../nephrology/nephrology-approach-ckd/" class="md-nav__link">
        Approach to Chronic Kidney Disease
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../nephrology/nephrology-common-side-effects-renal-transplant-immune-suppresants/" class="md-nav__link">
        Common Side Effects of Renal Transplant Immune Suppresants
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../nephrology/nephrology-hematuria/" class="md-nav__link">
        Hematuria
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../nephrology/nephrology-hypercalcemia/" class="md-nav__link">
        Hypercalcemia
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../nephrology/nephrology-hyperkalemia/" class="md-nav__link">
        Hyperkalemia
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../nephrology/nephrology-hypernatremia/" class="md-nav__link">
        Hypernatremia
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../nephrology/nephrology-hyperphosphatemia/" class="md-nav__link">
        Hyperphosphatemia
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../nephrology/nephrology-hypokalemia/" class="md-nav__link">
        Hypokalemia
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../nephrology/nephrology-hypomagnesemia/" class="md-nav__link">
        Hypomagnesemia
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../nephrology/nephrology-hyponatremia/" class="md-nav__link">
        Hyponatremia
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../nephrology/nephrology-hypophosphatemia/" class="md-nav__link">
        Hypophosphatemia
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../nephrology/nephrology-intravenous-fluids/" class="md-nav__link">
        Intravenous Fluids
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../nephrology/nephrology-metabolic-acidosis/" class="md-nav__link">
        Metabolic acidosis
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../nephrology/nephrology-peritonitis-patients-pd/" class="md-nav__link">
        Peritonitis in patients on PD
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../nephrology/nephrology-renal-replacement-therapy/" class="md-nav__link">
        Renal Replacement Therapy (RRT) Basics
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../nephrology/nephrology-transplant-aki/" class="md-nav__link">
        Transplant AKI
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../nephrology/nephrology-ua/" class="md-nav__link">
        UA
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../nephrology/nephrology-uti-renal-transplant/" class="md-nav__link">
        UTI in Renal Transplant
      </a>
    </li>
  

            
          
        </ul>
      </nav>
    </li>
  

    
      
      
      

  
  
  
    
    <li class="md-nav__item md-nav__item--nested">
      
      
        <input class="md-nav__toggle md-toggle" data-md-toggle="__nav_14" type="checkbox" id="__nav_14" >
      
      
      
      
        <label class="md-nav__link" for="__nav_14">
          Neurology
          <span class="md-nav__icon md-icon"></span>
        </label>
      
      <nav class="md-nav" aria-label="Neurology" data-md-level="1">
        <label class="md-nav__title" for="__nav_14">
          <span class="md-nav__icon md-icon"></span>
          Neurology
        </label>
        <ul class="md-nav__list" data-md-scrollfix>
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../neurology/main/" class="md-nav__link">
        Main
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../neurology/neurology-aidp/" class="md-nav__link">
        AIDP
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../neurology/neurology-als/" class="md-nav__link">
        ALS
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../neurology/neurology-ams/" class="md-nav__link">
        AMS
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../neurology/neurology-basic-seizures/" class="md-nav__link">
        Seizures
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../neurology/neurology-brain-masses/" class="md-nav__link">
        Brain Masses
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../neurology/neurology-elevated-icp-and-hydrocephalus/" class="md-nav__link">
        Elevated ICP and Hydrocephalus
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../neurology/neurology-inpatient-headache/" class="md-nav__link">
        Inpatient Headache
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../neurology/neurology-ms/" class="md-nav__link">
        MS
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../neurology/neurology-myasthenia-etc/" class="md-nav__link">
        Myasthenia etc
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../neurology/neurology-outpatient-headache/" class="md-nav__link">
        Outpatient Headache
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../neurology/neurology-parkinson/" class="md-nav__link">
        Parkinson
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../neurology/neurology-status-epilepticus/" class="md-nav__link">
        Status Epilepticus
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../neurology/neurology-stroke-0/" class="md-nav__link">
        Stroke
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../neurology/neurology-vertigo/" class="md-nav__link">
        Vertigo
      </a>
    </li>
  

            
          
        </ul>
      </nav>
    </li>
  

    
      
      
      

  
  
  
    
    <li class="md-nav__item md-nav__item--nested">
      
      
        <input class="md-nav__toggle md-toggle" data-md-toggle="__nav_15" type="checkbox" id="__nav_15" >
      
      
      
      
        <label class="md-nav__link" for="__nav_15">
          Ophthalmology
          <span class="md-nav__icon md-icon"></span>
        </label>
      
      <nav class="md-nav" aria-label="Ophthalmology" data-md-level="1">
        <label class="md-nav__title" for="__nav_15">
          <span class="md-nav__icon md-icon"></span>
          Ophthalmology
        </label>
        <ul class="md-nav__list" data-md-scrollfix>
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../ophthalmology/main/" class="md-nav__link">
        Main
      </a>
    </li>
  

            
          
        </ul>
      </nav>
    </li>
  

    
      
      
      

  
  
  
    
    <li class="md-nav__item md-nav__item--nested">
      
      
        <input class="md-nav__toggle md-toggle" data-md-toggle="__nav_16" type="checkbox" id="__nav_16" >
      
      
      
      
        <label class="md-nav__link" for="__nav_16">
          Outpatient medicine
          <span class="md-nav__icon md-icon"></span>
        </label>
      
      <nav class="md-nav" aria-label="Outpatient medicine" data-md-level="1">
        <label class="md-nav__title" for="__nav_16">
          <span class="md-nav__icon md-icon"></span>
          Outpatient medicine
        </label>
        <ul class="md-nav__list" data-md-scrollfix>
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../outpatient-medicine/main/" class="md-nav__link">
        Main
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../outpatient-medicine/outpatient-medicine-asthma/" class="md-nav__link">
        Asthma
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../outpatient-medicine/outpatient-medicine-coding-and-informatics/" class="md-nav__link">
        Coding and Informatics
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../outpatient-medicine/outpatient-medicine-hypertension/" class="md-nav__link">
        Hypertension
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../outpatient-medicine/outpatient-medicine-lipids/" class="md-nav__link">
        Lipids
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../outpatient-medicine/outpatient-medicine-obesitynutrition/" class="md-nav__link">
        Obesity/Nutrition
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../outpatient-medicine/outpatient-medicine-preventative-medicine/" class="md-nav__link">
        Preventative Medicine
      </a>
    </li>
  

            
          
        </ul>
      </nav>
    </li>
  

    
      
      
      

  
  
  
    
    <li class="md-nav__item md-nav__item--nested">
      
      
        <input class="md-nav__toggle md-toggle" data-md-toggle="__nav_17" type="checkbox" id="__nav_17" >
      
      
      
      
        <label class="md-nav__link" for="__nav_17">
          Pain and palliative
          <span class="md-nav__icon md-icon"></span>
        </label>
      
      <nav class="md-nav" aria-label="Pain and palliative" data-md-level="1">
        <label class="md-nav__title" for="__nav_17">
          <span class="md-nav__icon md-icon"></span>
          Pain and palliative
        </label>
        <ul class="md-nav__list" data-md-scrollfix>
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../pain-and-palliative/main/" class="md-nav__link">
        Main
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../pain-and-palliative/pain-and-palliative-acute-and-chronic-pain/" class="md-nav__link">
        Acute and Chronic Pain
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../pain-and-palliative/pain-and-palliative-code-status-discussion/" class="md-nav__link">
        Code Status Discussion
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../pain-and-palliative/pain-and-palliative-death-pronouncement/" class="md-nav__link">
        The Death Pronouncement
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../pain-and-palliative/pain-and-palliative-medications-dying-patients/" class="md-nav__link">
        Medications for Dying Patients
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../pain-and-palliative/pain-and-palliative-opiate-principles/" class="md-nav__link">
        Opiate Principles
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../pain-and-palliative/pain-and-palliative-video-examples-navigating-difficult-conversations/" class="md-nav__link">
        Video Examples for Navigating Difficult Conversations
      </a>
    </li>
  

            
          
        </ul>
      </nav>
    </li>
  

    
      
      
      

  
  
  
    
    <li class="md-nav__item md-nav__item--nested">
      
      
        <input class="md-nav__toggle md-toggle" data-md-toggle="__nav_18" type="checkbox" id="__nav_18" >
      
      
      
      
        <label class="md-nav__link" for="__nav_18">
          Physical medicine rehabilitation
          <span class="md-nav__icon md-icon"></span>
        </label>
      
      <nav class="md-nav" aria-label="Physical medicine rehabilitation" data-md-level="1">
        <label class="md-nav__title" for="__nav_18">
          <span class="md-nav__icon md-icon"></span>
          Physical medicine rehabilitation
        </label>
        <ul class="md-nav__list" data-md-scrollfix>
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../physical-medicine-rehabilitation/main/" class="md-nav__link">
        Main
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../physical-medicine-rehabilitation/physical-medicine-rehabilitation-back-pain/" class="md-nav__link">
        Back Pain
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../physical-medicine-rehabilitation/physical-medicine-rehabilitation-knee-pain/" class="md-nav__link">
        Knee Pain
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../physical-medicine-rehabilitation/physical-medicine-rehabilitation-neck-pain/" class="md-nav__link">
        Neck Pain
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../physical-medicine-rehabilitation/physical-medicine-rehabilitation-pmr-consultation/" class="md-nav__link">
        PM&R Consultation
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../physical-medicine-rehabilitation/physical-medicine-rehabilitation-rehabilitation-options/" class="md-nav__link">
        Rehabilitation Options
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../physical-medicine-rehabilitation/physical-medicine-rehabilitation-shoulder-pain/" class="md-nav__link">
        Shoulder Pain
      </a>
    </li>
  

            
          
        </ul>
      </nav>
    </li>
  

    
      
      
      

  
  
  
    
    <li class="md-nav__item md-nav__item--nested">
      
      
        <input class="md-nav__toggle md-toggle" data-md-toggle="__nav_19" type="checkbox" id="__nav_19" >
      
      
      
      
        <label class="md-nav__link" for="__nav_19">
          Procedures
          <span class="md-nav__icon md-icon"></span>
        </label>
      
      <nav class="md-nav" aria-label="Procedures" data-md-level="1">
        <label class="md-nav__title" for="__nav_19">
          <span class="md-nav__icon md-icon"></span>
          Procedures
        </label>
        <ul class="md-nav__list" data-md-scrollfix>
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../procedures/main/" class="md-nav__link">
        About
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../procedures/procedures-anesthesia/" class="md-nav__link">
        Anesthesia
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../procedures/procedures-anticoagulation-parameters/" class="md-nav__link">
        Anticoagulation Parameters
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../procedures/procedures-arterial-line/" class="md-nav__link">
        Arterial Line
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../procedures/procedures-central-line/" class="md-nav__link">
        Central line
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../procedures/procedures-consent/" class="md-nav__link">
        Consent
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../procedures/procedures-dht/" class="md-nav__link">
        DHT
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../procedures/procedures-lumbar-puncture/" class="md-nav__link">
        Lumbar Puncture
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../procedures/procedures-paracentesis/" class="md-nav__link">
        Paracentesis
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../procedures/procedures-thoracentesis/" class="md-nav__link">
        Thoracentesis
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../procedures/procedures-ultrasound-guided-peripheral-iv/" class="md-nav__link">
        Ultrasound-Guided Peripheral IV
      </a>
    </li>
  

            
          
        </ul>
      </nav>
    </li>
  

    
      
      
      

  
  
  
    
    <li class="md-nav__item md-nav__item--nested">
      
      
        <input class="md-nav__toggle md-toggle" data-md-toggle="__nav_20" type="checkbox" id="__nav_20" >
      
      
      
      
        <label class="md-nav__link" for="__nav_20">
          Psychiatry
          <span class="md-nav__icon md-icon"></span>
        </label>
      
      <nav class="md-nav" aria-label="Psychiatry" data-md-level="1">
        <label class="md-nav__title" for="__nav_20">
          <span class="md-nav__icon md-icon"></span>
          Psychiatry
        </label>
        <ul class="md-nav__list" data-md-scrollfix>
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../psychiatry/main/" class="md-nav__link">
        Main
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../psychiatry/psychiatry-agitation-management/" class="md-nav__link">
        Agitation Management
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../psychiatry/psychiatry-inpatient-insomnia/" class="md-nav__link">
        Inpatient Insomnia
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../psychiatry/psychiatry-medical-decision-making-capacity/" class="md-nav__link">
        Medical Decision-Making Capacity
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../psychiatry/psychiatry-medical-hold/" class="md-nav__link">
        Medical Hold
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../psychiatry/psychiatry-motivational-interviewing/" class="md-nav__link">
        Motivational Interviewing
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../psychiatry/psychiatry-personality-disorders/" class="md-nav__link">
        Personality Disorders
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../psychiatry/psychiatry-substance-use-disorder/" class="md-nav__link">
        Substance Use Disorder
      </a>
    </li>
  

            
          
        </ul>
      </nav>
    </li>
  

    
      
      
      

  
  
  
    
    <li class="md-nav__item md-nav__item--nested">
      
      
        <input class="md-nav__toggle md-toggle" data-md-toggle="__nav_21" type="checkbox" id="__nav_21" >
      
      
      
      
        <label class="md-nav__link" for="__nav_21">
          Pulmonary
          <span class="md-nav__icon md-icon"></span>
        </label>
      
      <nav class="md-nav" aria-label="Pulmonary" data-md-level="1">
        <label class="md-nav__title" for="__nav_21">
          <span class="md-nav__icon md-icon"></span>
          Pulmonary
        </label>
        <ul class="md-nav__list" data-md-scrollfix>
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../pulmonary/main/" class="md-nav__link">
        Main
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../pulmonary/pulmonary-acute-asthma-exacerbation/" class="md-nav__link">
        Acute Asthma Exacerbation
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../pulmonary/pulmonary-blood-gases/" class="md-nav__link">
        Blood Gases
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../pulmonary/pulmonary-cf-exacerbation/" class="md-nav__link">
        CF Exacerbation
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../pulmonary/pulmonary-copd-exacerbation-management/" class="md-nav__link">
        COPD Exacerbation Management
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../pulmonary/pulmonary-cxrs/" class="md-nav__link">
        CXRs
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../pulmonary/pulmonary-hemoptysis/" class="md-nav__link">
        Hemoptysis
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../pulmonary/pulmonary-home-oxygen-therapies/" class="md-nav__link">
        Home Oxygen Therapies
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../pulmonary/pulmonary-hypoxia/" class="md-nav__link">
        Hypoxia
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../pulmonary/pulmonary-ild/" class="md-nav__link">
        ILD
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../pulmonary/pulmonary-pfts/" class="md-nav__link">
        PFTs
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../pulmonary/pulmonary-pleural-effusions/" class="md-nav__link">
        Pleural Effusions
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../pulmonary/pulmonary-pulmonary-hypertension/" class="md-nav__link">
        Pulmonary Hypertension
      </a>
    </li>
  

            
          
        </ul>
      </nav>
    </li>
  

    
      
      
      

  
  
  
    
    <li class="md-nav__item md-nav__item--nested">
      
      
        <input class="md-nav__toggle md-toggle" data-md-toggle="__nav_22" type="checkbox" id="__nav_22" >
      
      
      
      
        <label class="md-nav__link" for="__nav_22">
          Radiology
          <span class="md-nav__icon md-icon"></span>
        </label>
      
      <nav class="md-nav" aria-label="Radiology" data-md-level="1">
        <label class="md-nav__title" for="__nav_22">
          <span class="md-nav__icon md-icon"></span>
          Radiology
        </label>
        <ul class="md-nav__list" data-md-scrollfix>
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../radiology/radiology-consults-radiology-procedures/" class="md-nav__link">
        Consults for Radiology Procedures
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../radiology/radiology-cxr/" class="md-nav__link">
        Basic Chest X-ray Interpretation
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../radiology/radiology-kub/" class="md-nav__link">
        Basic Abdominal X-ray Interpretation
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../radiology/radiology-radiology-exams-diagnosis/" class="md-nav__link">
        Common Radiology Exams by Suspected Diagnosis
      </a>
    </li>
  

            
          
        </ul>
      </nav>
    </li>
  

    
      
      
      

  
  
  
    
    <li class="md-nav__item md-nav__item--nested">
      
      
        <input class="md-nav__toggle md-toggle" data-md-toggle="__nav_23" type="checkbox" id="__nav_23" >
      
      
      
      
        <label class="md-nav__link" for="__nav_23">
          Rheumatology
          <span class="md-nav__icon md-icon"></span>
        </label>
      
      <nav class="md-nav" aria-label="Rheumatology" data-md-level="1">
        <label class="md-nav__title" for="__nav_23">
          <span class="md-nav__icon md-icon"></span>
          Rheumatology
        </label>
        <ul class="md-nav__list" data-md-scrollfix>
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../rheumatology/main/" class="md-nav__link">
        Main
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../rheumatology/rheumatology-biologic-overview/" class="md-nav__link">
        Biologic Overview
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../rheumatology/rheumatology-common-rheumatologic-diseases/" class="md-nav__link">
        Common Rheumatologic Diseases
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../rheumatology/rheumatology-crystal-arthropathy/" class="md-nav__link">
        Crystal Arthropathy
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../rheumatology/rheumatology-inflammatory-myopathies/" class="md-nav__link">
        Inflammatory Myopathies
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../rheumatology/rheumatology-rheumatology-lab-testing/" class="md-nav__link">
        Rheumatology Lab Testing
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../rheumatology/rheumatology-vasculitis/" class="md-nav__link">
        Vasculitis
      </a>
    </li>
  

            
          
        </ul>
      </nav>
    </li>
  

    
      
      
      

  
  
  
    
    <li class="md-nav__item md-nav__item--nested">
      
      
        <input class="md-nav__toggle md-toggle" data-md-toggle="__nav_24" type="checkbox" id="__nav_24" >
      
      
      
      
        <label class="md-nav__link" for="__nav_24">
          Toxicology
          <span class="md-nav__icon md-icon"></span>
        </label>
      
      <nav class="md-nav" aria-label="Toxicology" data-md-level="1">
        <label class="md-nav__title" for="__nav_24">
          <span class="md-nav__icon md-icon"></span>
          Toxicology
        </label>
        <ul class="md-nav__list" data-md-scrollfix>
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../toxicology/toxicology-brown-recluse-loxoscelism/" class="md-nav__link">
        Brown Recluse Bites (Loxoscelism)
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../toxicology/toxicology-overdose-management/" class="md-nav__link">
        Management of Specific Overdoses
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../toxicology/toxicology-qtc/" class="md-nav__link">
        Drug-Induced QTc Prolongation
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../toxicology/toxicology-toxidrome-overview/" class="md-nav__link">
        Toxidrome Overview
      </a>
    </li>
  

            
          
        </ul>
      </nav>
    </li>
  

    
      
      
      

  
  
  
    
    <li class="md-nav__item md-nav__item--nested">
      
      
        <input class="md-nav__toggle md-toggle" data-md-toggle="__nav_25" type="checkbox" id="__nav_25" >
      
      
      
      
        <label class="md-nav__link" for="__nav_25">
          zCBH
          <span class="md-nav__icon md-icon"></span>
        </label>
      
      <nav class="md-nav" aria-label="zCBH" data-md-level="1">
        <label class="md-nav__title" for="__nav_25">
          <span class="md-nav__icon md-icon"></span>
          zCBH
        </label>
        <ul class="md-nav__list" data-md-scrollfix>
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../zCBH/cprs/" class="md-nav__link">
        CPRS
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../zCBH/va-notes/" class="md-nav__link">
        VA notes
      </a>
    </li>
  

            
          
        </ul>
      </nav>
    </li>
  

    
      
      
      

  
  
  
    
    <li class="md-nav__item md-nav__item--nested">
      
      
        <input class="md-nav__toggle md-toggle" data-md-toggle="__nav_26" type="checkbox" id="__nav_26" >
      
      
      
      
        <label class="md-nav__link" for="__nav_26">
          Appendices
          <span class="md-nav__icon md-icon"></span>
        </label>
      
      <nav class="md-nav" aria-label="Appendices" data-md-level="1">
        <label class="md-nav__title" for="__nav_26">
          <span class="md-nav__icon md-icon"></span>
          Appendices
        </label>
        <ul class="md-nav__list" data-md-scrollfix>
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../appendices/appendices-discharge-va/" class="md-nav__link">
        How to Discharge a Patient at VA
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../appendices/appendices-discharge-vumc/" class="md-nav__link">
        How to Discharge a Patient at VUMC
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../appendices/appendices-door-codes/" class="md-nav__link">
        VUMC and VA Door Codes and Ultrasound Locations
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../appendices/appendices-phone-numbers/" class="md-nav__link">
        Phone and Pager Directory
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../appendices/appendices-rotations-va/" class="md-nav__link">
        Interns' Guide to Rotations at VA
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../appendices/appendices-rotations-vumc/" class="md-nav__link">
        VUMC Rotations
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../appendices/appendices-uploading-records/" class="md-nav__link">
        Uploading Records to EPIC
      </a>
    </li>
  

            
          
        </ul>
      </nav>
    </li>
  

    
      
      
      

  
  
  
    <li class="md-nav__item">
      <a href="../../print_page/" class="md-nav__link">
        Print Site
      </a>
    </li>
  

    
  </ul>
</nav>
                  </div>
                </div>
              </div>
            
            
              
              <div class="md-sidebar md-sidebar--secondary" data-md-component="sidebar" data-md-type="toc" >
                <div class="md-sidebar__scrollwrap">
                  <div class="md-sidebar__inner">
                    

<nav class="md-nav md-nav--secondary" aria-label="Table of contents">
  
  
  
  
</nav>
                  </div>
                </div>
              </div>
            
          
          <div class="md-content" data-md-component="content">
            <article class="md-content__inner md-typeset">
              
                
  <a href="https://github.com/vanderbilt-internal-medicine/vimbook/edit/main/docs/hematology-oncology/main.md" title="Edit this page" class="md-content__button md-icon">
    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M20.71 7.04c.39-.39.39-1.04 0-1.41l-2.34-2.34c-.37-.39-1.02-.39-1.41 0l-1.84 1.83 3.75 3.75M3 17.25V21h3.75L17.81 9.93l-3.75-3.75L3 17.25Z"/></svg>
  </a>



  <h1>Main</h1>

<p>Anemia – Margaret Wheless</p>
<p>Presentation</p>
<ul>
<li>Symptoms:</li>
</ul>
<!-- -->

<ul>
<li>Fatigue/malaise, dyspnea on exertion, angina (if history of CAD)</li>
</ul>
<!-- -->

<ul>
<li>Signs:</li>
</ul>
<!-- -->

<ul>
<li>
<p>Pallor, tachycardia, orthostatic hypotension, purpura, glossitis,
    koilonychia (in IDA)</p>
</li>
<li>
<p>Jaundice (if hemolysis)</p>
</li>
<li>
<p>Splenomegaly: suggests extramedullary hematopoiesis or sequestration</p>
</li>
<li>
<p>Neurologic symptoms: suggests B12 deficiency</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>CBC w/diff, reticulocyte count, peripheral blood smear, Iron studies
    (TIBC, Ferritin)</li>
</ul>
<!-- -->

<ul>
<li>
<p>RI > 2%: blood loss vs hemolysis; see below</p>
<ul>
<li>Hemolysis labs: Bilirubin, LDH, haptoglobin</li>
</ul>
</li>
<li>
<p>RI \&lt; 2%: hypoproliferative stratify based on RBC size</p>
<ul>
<li>Microcytic (\&lt;80) vs. Normocytic (80-100) vs. Macrocytic (>100)</li>
</ul>
</li>
</ul>
<p>Reticulocyte Index > 2%</p>
<p>Background</p>
<ul>
<li>Etiology: Consumption vs Blood loss</li>
</ul>
<!-- -->

<ul>
<li>
<p>Loss: acute bleed vs iatrogenic from labs</p>
</li>
<li>
<p>Hemolysis: Microangiopathic hemolytic anemia (MAHA), autoimmune
    hemolytic anemia (AIHA), intrinsic RBC defects</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<p>LDH, ↑indirect bilirubin, ↓haptoglobin, PT/PTT</p>
</li>
<li>
<p>Peripheral blood smear: evaluated for schistocytes, bite cells, spur
    cells, spherocytes, etc.</p>
</li>
<li>
<p>Direct antiglobulin test (DAT) to evaluate for autoimmune hemolytic
    anemia</p>
</li>
</ul>
<p>Extrinsic RBC causes:</p>
<ul>
<li>
<p>If schistocytes ± thrombocytopenia = MAHA: TTP, DIC, HUS, HELLP,
    mechanical valves, malignant HTN, cocaine, scleroderma renal crisis</p>
</li>
<li>
<p>If DAT positive = AIHA</p>
</li>
</ul>
<p>Intrinsic RBC causes:</p>
<ul>
<li>
<p>Sickle cell disease: chronic hemolysis + splenic sequestration
    crisis where RI is↑ vs aplastic crisis where RI is↓ (see sickle cell
    section)</p>
</li>
<li>
<p>Hereditary spherocytosis</p>
</li>
<li>
<p>Hereditary elliptocytosis</p>
</li>
<li>
<p>PNH</p>
</li>
<li>
<p>G6PD: bite cells, Heinz bodies</p>
</li>
</ul>
<!-- -->

<ul>
<li>Usually precipitated by drugs: nitrofurantoin, dapsone,
    sulfonamides, rasburicase, primaquine</li>
</ul>
<p>Management</p>
<ul>
<li>MAHA</li>
</ul>
<!-- -->

<ul>
<li>
<p>DIC: sepsis, malignancy, pregnancy</p>
<ul>
<li>
<p>Treat underlying cause</p>
</li>
<li>
<p>If active bleeding: FFP, cryoprecipitate (to keep
    fibrinogen>100) and platelets</p>
</li>
</ul>
</li>
<li>
<p>TTP: Order ADAMTS13 (prior to plasma transfusion or exchange)</p>
<ul>
<li>If concern for TTP you should immediately consult Heme and
    Nephrology</li>
</ul>
</li>
<li>
<p>HUS: + shiga toxin, AKI, diarrhea</p>
</li>
</ul>
<!-- -->

<ul>
<li>AIHA:</li>
</ul>
<!-- -->

<ul>
<li>
<p>Cold (rare): IgM binds at temp \&lt;37</p>
<ul>
<li>
<p>Caused by lymphoproliferative disorder (Waldenström
    Macroglobulinemia), mycoplasma, EBV, HIV</p>
</li>
<li>
<p>Consult heme. Treat underlying. Consider rituximab (steroids
    ineffective)</p>
</li>
</ul>
</li>
<li>
<p>Warm: IgG</p>
<ul>
<li>
<p>Idiopathic or associated with lymphoma, SLE, drugs, babesiosis,
    HIV</p>
</li>
<li>
<p>Can use steroids, IVIG, rituximab</p>
</li>
</ul>
</li>
</ul>
<p>RBC Size Framework</p>
<p>Normocytic Anemia: MCV 80-100</p>
<ul>
<li>Etiologies:</li>
</ul>
<!-- -->

<ul>
<li>
<p>Anemia of inflammation: (may also be microcytic)</p>
</li>
<li>
<p>Anemia of CKD: low Erythropoietin (EPO) levels</p>
</li>
<li>
<p>Endocrine disease (hypothyroidism, adrenal insufficiency):
    ↓metabolic demand/O2 requirement</p>
</li>
<li>
<p>Mixed macrocytic/microcytic disease may have a normal MCV: look for
    ↑RDW</p>
</li>
<li>
<p>Pure red cell aplasia: associated with destructive Ab (CLL, thymoma,
    parvovirus, autoimmune)</p>
</li>
<li>
<p>Paroxysmal nocturnal hemoglobinuria (PNH)</p>
</li>
<li>
<p>Splenic sequestration</p>
</li>
<li>
<p>Bone marrow failure or infiltration (typically will see
    pancytopenia)</p>
</li>
</ul>
<!-- -->

<ul>
<li>Bone marrow biopsy may be indicated if no identifiable cause or
    anemia is associated with other cytopenia’s</li>
</ul>
<p>Microcytic anemia: MCV \&lt;80 (mnemonic: SALTI)</p>
<ul>
<li>Sideroblastic, Anemia of chronic disease, Lead poisoning,
    Thalassemia and Iron-deficiency</li>
</ul>
<table>
<colgroup>
<col style="width: 18%" />
<col style="width: 26%" />
<col style="width: 25%" />
<col style="width: 29%" />
</colgroup>
<thead>
<tr class="header">
<th>Disease</th>
<th>Etiology</th>
<th>Evaluation</th>
<th>Considerations</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Sideroblastic</td>
<td><p>MDS</p>
<p>Idiopathic</p>
<p>EtOH, Lead, Isoniazid</p>
<p>Cu deficiency</p></td>
<td><p>Social hx, TB, consider Lead level</p>
<p>Fe: ↑↑</p>
<p>Ferritin: ↑ to nL</p>
<p>TIBC: nL</p>
<p>Smear: basophilic stippling</p>
<p>BMBx: ringed sideroblasts</p></td>
<td>In clinical practice this is usually acquired; either due to alcohol
(can resolved with cessation) or primary bone marrow disorder (e.g.
MDS-RARS)</td>
</tr>
<tr class="even">
<td>Anemia of Inflammation (formerly chronic disease)</td>
<td>Chronic inflammation, malignancy, HIV, autoimmune dz, heart failure,
etc.</td>
<td><p>Fe/TIBC &gt;18%</p>
<p>Fe: ↓↓</p>
<p>Ferritin: ↑↑</p>
<p>TIBC: ↓↓</p></td>
<td><p>Treat underlying disease</p>
<p>Replete Fe if ferritin &lt;100 or TIBC &lt;20%</p>
<p>EPO if Hgb &lt;10 and serum EPO &lt;10</p></td>
</tr>
<tr class="odd">
<td>Thalassemia</td>
<td><p>↓ synthesis of α or β chains leads to ↓ erythropoiesis and ↑
hemolysis</p>
<p>Family Hx of anemia</p></td>
<td><p>Mentzer’s index: MCV/RBC &lt;13 = thalassemia</p>
<p>Normal Fe studies; can mimic microcytic anemia and Fe overload from
transfusions</p>
<p>Diagnosis: Hb electrophoresis (α will be normal)</p></td>
<td><p>α-thal more common in Asian/African descent</p>
<p>β thal common in Mediterranean descent</p>
<p>Tx: transfusions, folate, Fe chelator depending on severity</p></td>
</tr>
<tr class="even">
<td>Iron (Fe) deficiency</td>
<td><p>Chronic bleeding: colon cancer, heavy menstrual periods,
cirrhosis (portal gastropathy)</p>
<p>Supply: malnutrition, Crohn’s dz, Celiac dz, subtotal gastrectomy</p>
<p>Demand: pregnancy</p></td>
<td><p>Fe/TIBC &lt;18%</p>
<p>Fe:↓↓ TIBC:↑ nl to ↑</p>
<p>Ferritin: &lt; 100</p>
<p>Mentzer’s index: &gt;13</p>
<p>Consider celiac testing based on clinical suspicion</p>
<p>Investigate for GIB or source of blood loss</p></td>
<td><p>Oral Fe: 6wks to correct anemia, 6mo to replete stores; dose
every other day (↑ absorption w/ ↓ GI side effects); add Vit C for ↑
absorption</p>
<p>If can’t tolerate PO consider IV Fe (Avoid when bacteremic)</p>
<p>HFrEF: IV Fe if ferritin &lt;100 OR 100-300 w/ Fe sat
&lt;20%</p></td>
</tr>
</tbody>
</table>

<p>Macrocytic Anemia: MCV >100</p>
<ul>
<li>Non-megaloblastic:</li>
</ul>
<!-- -->

<ul>
<li>
<p>ETOH, liver disease, hypothyroidism, MDS</p>
</li>
<li>
<p>Medications that impair DNA synthesis: zidovudine, 5-FU,
    hydroxyurea, ara-C, AZT, MTX</p>
</li>
</ul>
<!-- -->

<ul>
<li>Megaloblastic</li>
</ul>
<!-- -->

<ul>
<li>
<p>B12 deficiency</p>
<ul>
<li>
<p>Presentation: neurologic changes (subacute combined
    degeneration), paresthesia, ataxia, dementia (reversible with
    early treatment)</p>
</li>
<li>
<p>Etiology: malnutrition (alcoholics, vegan), pernicious anemia,
    gastrectomy, Crohn’s disease, chronic pancreatitis, celiac
    disease</p>
</li>
<li>
<p>Diagnosis: ↓B12, ↑MMA, ↑homocysteine</p>
</li>
<li>
<p>Treatment: either monthly IM or sublingual B12 (oral not
    absorbed if no IF)</p>
</li>
</ul>
</li>
<li>
<p>Folate deficiency</p>
<ul>
<li>
<p>Etiology: malnutrition, decreased absorption (e.g. Celiac
    disease), impaired metabolism (MTX, TMP), ↑requirement
    (hemolysis, malignancy, dialysis)</p>
</li>
<li>
<p>Diagnosis: ↓folate, ↑homocysteine, MMA will be normal</p>
</li>
<li>
<p>Treatment: PO folate 1-4 mg daily</p>
</li>
</ul>
</li>
</ul>
<p>Neutropenia &amp; Neutropenic Fever – Jennifer Marvin-Peek</p>
<p>Background</p>
<ul>
<li>Neutropenia: absolute neutrophil count (ANC) \&lt; 1500</li>
</ul>
<!-- -->

<ul>
<li>Severe neutropenia: absolute neutrophil count (ANC) \&lt;500 (Use
    manual count if available)</li>
</ul>
<table>
<colgroup>
<col style="width: 18%" />
<col style="width: 26%" />
<col style="width: 55%" />
</colgroup>
<thead>
<tr class="header">
<th>Mechanism</th>
<th>Causes</th>
<th>Example (s)</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td rowspan="6">Neutrophil production</td>
<td>Drug associated</td>
<td><p>Cytotoxic or immunosuppressive agents</p>
<p>Methimazole, PTU, Colchicine</p>
<p>Macrolides, Bactrim, Dapsone, Vancomycin</p>
<p>Amphotericin, Acyclovir, Ganciclovir</p>
<p>TCAs, Clozapine, Carbamazepine, Valproate</p>
<p>ACEI, Digoxin, Propranolol, Procainamide</p></td>
</tr>
<tr class="even">
<td>Radiation exposure</td>
<td></td>
</tr>
<tr class="odd">
<td>Malignancies</td>
<td>Leukemias, MDS</td>
</tr>
<tr class="even">
<td>Infection</td>
<td><p>Hepatitis, HIV, EBV, CMV</p>
<p>Rickettsia, Tularemia, Typhoid, TB</p></td>
</tr>
<tr class="odd">
<td>Nutritional deficiency</td>
<td>Vitamin B12, Folate, Copper</td>
</tr>
<tr class="even">
<td>Other</td>
<td>Aplastic anemia, Benign ethnic neutropenia</td>
</tr>
<tr class="odd">
<td>Redistribution</td>
<td>Splenomegaly</td>
<td>Margination and sequestration</td>
</tr>
<tr class="even">
<td>Congenital</td>
<td>Genetics</td>
<td>Benign ethnic neutropenia, familial neutropenia</td>
</tr>
<tr class="odd">
<td rowspan="2">Immune destruction</td>
<td>Autoimmune disorders</td>
<td>RA, SLE</td>
</tr>
<tr class="even">
<td>Other</td>
<td>Autoimmune neutropenia</td>
</tr>
</tbody>
</table>

<p>Management</p>
<ul>
<li>If ANC \&lt;500</li>
</ul>
<!-- -->

<ul>
<li>
<p>Check all lines/IVs for erythema and induration daily</p>
</li>
<li>
<p>Check mouth for mucositis, mouth care after meals and before bed</p>
</li>
<li>
<p>Assess for Neutropenic Fever &amp; Complications – see below</p>
</li>
<li>
<p>Evaluate for indications for prophylaxis – see below</p>
</li>
<li>
<p>No evidence to support use of neutropenic diet</p>
</li>
<li>
<p>No digital rectal exams or enemas/suppositories (risk of bacterial
    translocation)</p>
</li>
</ul>
<p>Neutropenic Fever</p>
<ul>
<li>
<p>ANC \&lt;500 and T> 100.4 °F or 38.0 °C</p>
</li>
<li>
<p>Neutropenic pts are unable to mount an adequate immune response and
    can become critically ill very quickly</p>
</li>
<li>
<p>Do not wait for a temp re-check, you need to start antibiotics
    immediately</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<p>Chest X-ray</p>
</li>
<li>
<p>Two sets of blood cultures (one from PICC/port if present)</p>
</li>
<li>
<p>Urinalysis AND urine culture (not the reflex order set)</p>
</li>
<li>
<p>If diarrhea, get C. diff PCR</p>
</li>
<li>
<p>If abdominal pain, get CT A/P with IV contrast</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>Empirically treat with Cefepime</p>
</li>
<li>
<p>Indications for Vancomycin:</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Hemodynamically unstable</p>
</li>
<li>
<p>Severe mucositis</p>
</li>
<li>
<p>Focal consolidation on CXR</p>
</li>
<li>
<p>Erythema/induration around line</p>
</li>
<li>
<p>Concern for skin/soft tissue infection</p>
</li>
<li>
<p>GPCs in blood</p>
</li>
<li>
<p>Fever continues >24h on cefepime</p>
</li>
</ul>
<!-- -->

<ul>
<li>Additional Coverage:</li>
</ul>
<!-- -->

<ul>
<li>
<p>If abdominal pain/diarrhea: Flagyl 500mg q8h</p>
</li>
<li>
<p>Concern for C-diff: PO Vancomycin 125mg q6h</p>
</li>
<li>
<p>Still fevering on Cefepime at 72 hrs (differs by attending)
    Meropenem</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Fungal coverage: Consider if risk factors (TPN) or persistent fevers
    (>72hrs)</p>
<ul>
<li>Micafungin 100 mg IV daily or Voriconazole 200mg PO BID</li>
</ul>
</li>
</ul>
<p>Neutropenic Complications</p>
<p>Mucositis</p>
<ul>
<li>
<p>Can range from mouth soreness to severe erosions preventing
    eating/drinking</p>
</li>
<li>
<p>Can become secondarily infected with Candida, HSV</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Management:</p>
<ul>
<li>
<p>Routine oral care with a soft toothbrush to remove plaque</p>
</li>
<li>
<p>Oral rinses with saline and/or sodium bicarbonate</p>
</li>
<li>
<p>Magic mouthwash for symptomatic relief (or viscous lidocaine at
    the VA)</p>
</li>
<li>
<p>Typically recovers quickly when ANC > 500</p>
</li>
</ul>
</li>
</ul>
<p>Neutropenic enterocolitis (Typhlitis)</p>
<ul>
<li>
<p>Life-threatening bacterial translocation due to breakdown of
    gut-mucosal barrier</p>
</li>
<li>
<p>Presentation: Abdominal pain + fever</p>
</li>
</ul>
<!-- -->

<ul>
<li>&plusmn; abdominal distension, nausea, vomiting, watery and/or bloody
    diarrhea</li>
</ul>
<!-- -->

<ul>
<li>
<p>Diagnosis: CT A/P with contrast, consider C. diff PCR if diarrhea</p>
</li>
<li>
<p>Treatment:</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Cefepime/Flagyl OR Zosyn</p>
</li>
<li>
<p>If no perforation/abscess on CT scan, typically continue until 14
    days after ANC recovers >500 and abdominal pain resolves</p>
</li>
<li>
<p>Can change to cipro/flagyl once ANC >500</p>
</li>
<li>
<p>If perforation/abscess: will need imaging to confirm resolution, and
    longer duration of abx</p>
</li>
</ul>
<p>Neutropenic Prophylaxis</p>
<ul>
<li>Used if ANC is expected to be \&lt; 500 for > 7 days</li>
</ul>
<table>
<colgroup>
<col style="width: 19%" />
<col style="width: 33%" />
<col style="width: 46%" />
</colgroup>
<thead>
<tr class="header">
<th></th>
<th>Most Common Regimens</th>
<th>Alternatives</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Bacterial</td>
<td>Levofloxacin 500mg daily (renally dosed)</td>
<td>Cefdinir 300mg BID</td>
</tr>
<tr class="even">
<td>Viral</td>
<td>Valacyclovir 500mg BID</td>
<td>Acyclovir 400mg BID (renally dosed)</td>
</tr>
<tr class="odd">
<td>Fungal</td>
<td>Fluconazole 400mg daily</td>
<td><p>Posaconazole 300mg BID x2 days 300mg daily (AML induction for
aspergillus)</p>
<p>Micafungin 50mg IV daily</p></td>
</tr>
<tr class="even">
<td>PJP (if steroids)</td>
<td>Inhaled pentamidine 300mg qmonthly</td>
<td><p>Dapsone (check G6PD)</p>
<p>Avoid Bactrim (risk of myelosuppression)</p></td>
</tr>
</tbody>
</table>

<p>Filgrastim (G-CSF – Neupogen/Zarxio /Granix)</p>
<ul>
<li>
<p>Induces bone marrow production of neutrophils</p>
</li>
<li>
<p>Dose: either 300mcg or 480mcg (rounded from 5 mcg/kg/day)</p>
</li>
<li>
<p>Common side effects: fatigue, nausea</p>
</li>
<li>
<p>PEG-filgrastim (Neulasta): long-acting version that is only given as
    an outpatient</p>
</li>
</ul>
<p>Thrombocytopenia – Robert Dunn</p>
<p>Background</p>
<ul>
<li>
<p>Platelet count \&lt;150k (mild), 50-100k (moderate), \&lt;50k (severe)</p>
</li>
<li>
<p>Framework for differential: consumption, sequestration, destruction,
    production</p>
</li>
<li>
<p>Causes to consider:</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Can’t Miss Diagnoses: TTP, HUS, HELLP, DIC, HIT</p>
</li>
<li>
<p>Platelet clumping (lab artifact - pseudothrombocytopenia)</p>
</li>
<li>
<p>Splenomegaly can represent: Plt sequestration, cirrhosis, portal
    hypertension</p>
</li>
<li>
<p>Drug-induced: (Antibiotics, heparin, chemo, GpIIb/IIIa antagonists,
    H2-antagonists)</p>
</li>
<li>
<p>Rheumatologic cause – SLE, sarcoidosis, scleroderma renal crisis</p>
</li>
<li>
<p>Sepsis, independent of DIC</p>
</li>
<li>
<p>Immune thrombocytopenia (ITP) is a diagnosis of exclusion</p>
</li>
<li>
<p>Massive physiologic consumption: large hematoma, active hemorrhage</p>
</li>
<li>
<p>Cirrhosis – results in low thrombopoietin (TPO) and increased
    clearance</p>
</li>
<li>
<p>Chronic alcohol use – direct marrow suppression</p>
</li>
<li>
<p>Infections: HIV, HCV, EBV, Parvovirus, Rickettsia, H. pylori, CMV</p>
</li>
<li>
<p>Bone marrow failure: aplastic anemia, MDS, leukemia, chemotherapy</p>
</li>
<li>
<p>Dilutional: fluid resuscitation and massive transfusion</p>
</li>
</ul>
<p>Presentation</p>
<ul>
<li>
<p>Petechiae – typically begins distally on lower legs (in mouth = wet
    purpura), seen when \&lt;10-20k</p>
</li>
<li>
<p>Overt bleeding, mucosal bleeding, epistaxis (seen when \&lt;20k)</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<p>CMP, CBC w/diff, peripheral smear, citrated platelet count, immature
    platelet fraction (IPF)</p>
</li>
<li>
<p>LDH, Fibrinogen, d-dimer, PT/aPTT</p>
</li>
<li>
<p>Determine timing of decline as well as prior values</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Look at other cell lines - never normal to have two cytopenia’s</p>
</li>
<li>
<p>Review recent initiation of drugs: (heparin, antibiotics, and
    chemotherapy)</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Consider abdominal ultrasound to look for splenomegaly and liver
    pathology</p>
</li>
<li>
<p>Infectious work up (HIV, HCV)</p>
</li>
<li>
<p>Calculate 4T Score and consider your pretest probability for HIT
    testing</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>HIT Ab: ELISA is first test – only run once/day at VUMC so order
    early if considering</p>
</li>
<li>
<p>Reflex Serotonin release assay (SRA) for confirmation (VUMC performs
    reflexive testing)</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>Plt \&lt;50k</li>
</ul>
<!-- -->

<ul>
<li>
<p>Discontinue pharmacologic DVT prophylaxis (unless HIT)</p>
</li>
<li>
<p>If on anticoagulation: consider risk/benefits of continued
    anticoagulation</p>
<ul>
<li>Can transfuse plt’s if AC is mandatory</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Plt \&lt;10k</li>
</ul>
<!-- -->

<ul>
<li>
<p>Transfuse platelets given risk of spontaneous intracranial
    hemorrhage</p>
</li>
<li>
<p>In pt’s with HIT or TTP, there is theoretical concern that
    transfusing plt can “fuel the fire” and lead to more thrombosis, but
    if there is active bleeding then consider platelets</p>
<ul>
<li>Therefore, bleeding with HIT or TTP, discuss with Hematology
    before transfusion</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>HIT</li>
</ul>
<!-- -->

<ul>
<li>
<p>If pretest probability is high or HIT is confirmed</p>
</li>
<li>
<p>Stop Unfractionated and low molecular weight heparin products</p>
</li>
<li>
<p>Start Argatroban gtt</p>
</li>
</ul>
<!-- -->

<ul>
<li>If schistocytes present on peripheral smear = concern for TTP</li>
</ul>
<!-- -->

<ul>
<li>
<p>Draw ADAMTS13</p>
</li>
<li>
<p>Contact Nephrology and Hematology for PLEX</p>
</li>
</ul>
<p>Additional Information</p>
<ul>
<li>Clumping on lab draws:</li>
</ul>
<!-- -->

<ul>
<li>Obtain Citrated platelet (“blue top” tube – CPRS refers to it as a
    blue top platelet count)</li>
</ul>
<!-- -->

<ul>
<li>If no resolution, obtain a "Gold top" LAB 301 in Epic (Named: Plt
    count) (ACD tube)</li>
</ul>
<p>Pancytopenia – Thomas Gracie</p>
<p>Background</p>
<ul>
<li>Framework for differential:</li>
</ul>
<!-- -->

<ul>
<li>
<p>Impaired production (aplastic anemia, marrow infiltration, marrow
    suppression, vitamin/nutritional deficiencies, sepsis, cirrhosis)</p>
</li>
<li>
<p>Peripheral destruction (autoimmune hemolytic, hypersplenism)</p>
</li>
<li>
<p>Combined process (PNH, SLE, leukemia, HLH, infections)</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<p>Medications: NSAIDs, AEDs, steroids, chemotherapy, antivirals,
    immunosuppression</p>
</li>
<li>
<p>PMHx: autoimmune disease (SLE, RA), radiation, gastric surgery,
    malabsorption, liver disease, hematologic malignancy</p>
</li>
<li>
<p>Social Hx: EtOH use, malnutrition, occupational exposures, exposures
    to TB or leishmaniasis</p>
</li>
<li>
<p>Exam: lymphadenopathy, hepatosplenomegaly, neuropathy, petechiae,
    stigmata of liver disease, cachexia</p>
</li>
<li>
<p>Diagnostic studies: CBC w/ diff, CMP, reticulocyte count, peripheral
    smear, viral studies (hepatitis A/B/C, EBV, CMV, HIV, parvovirus
    B19), vitamin levels (B12, folate, copper, zinc), iron studies,
    hemolysis labs (LDH, haptoglobin, Coombs), flow cytometry, bone
    marrow biopsy, cytogenetics and FISH</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>For pancytopenia that is acute (hospital onset) often observation is
    the best approach</p>
</li>
<li>
<p>When pancytopenia is slow, progressive over time, or acute without
    any other precipitating factors then would consult hematology for
    consideration of a bone marrow syndromes</p>
</li>
</ul>
<p>Leukocytosis – Kenna Koehler</p>
<p>Background</p>
<ul>
<li>
<p>Common progenitor cells (stem cells) are located in the bone marrow
    and give rise to erythrocytes, myeloblasts, megakaryoblasts</p>
</li>
<li>
<p>Normal WBC can vary by age and pregnancy, for the purpose of this
    section will assume this is for an average, non-pregnant adult</p>
</li>
<li>
<p>Chronic mild neutrophilic leukocytosis (10-20k) is common with
    tobacco use and obesity, both due to mechanisms related to chronic
    inflammation</p>
</li>
<li>
<p>Reactive (typically 11k-30k) - surgery, exercise, trauma, burns,
    emotional stress</p>
</li>
<li>
<p>Leukemoid reaction (typically 50k-100k) - severe infections
    (fulminant <em>C difficile</em>), organ rejection</p>
</li>
<li>
<p>If greater than 100k, think leukemia or myeloproliferative disorder</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Neutrophilia (neutrophil count >7k)</li>
</ul>
<!-- -->

<ul>
<li>Bacterial infection, pregnancy, rheumatologic disease, steroids,
    beta agonists, lithium, colony-stimulating factors, splenectomy or
    functional asplenia, congenital (hereditary/chronic idiopathic
    neutrophilia), Down syndrome, leukocyte adhesion deficiency,
    malignancy, smoking, obesity</li>
</ul>
<!-- -->

<ul>
<li>Lymphocytosis (>40% of WBC count or >4,500k/mm<sup>3</sup>)</li>
</ul>
<!-- -->

<ul>
<li>Infections (pertussis, syphilis, CMV, EBV, hepatitis A/B/C, toxo),
    hypersensitivity reactions, thyrotoxicosis, Addison's disease,
    hematologic malignancies, “reactive”</li>
</ul>
<!-- -->

<ul>
<li>Monocytosis (>8% of WBC count or >880/mm<sup>3</sup>)</li>
</ul>
<!-- -->

<ul>
<li>Infections (TB, fungal disease, protozoa, tick-borne), autoimmune
    disease, malignancy (CMML)</li>
</ul>
<!-- -->

<ul>
<li>Eosinophilia (>500/mm<sup>3</sup>)</li>
</ul>
<!-- -->

<ul>
<li>
<p>Hypersensitivity (asthma, urticaria, atopic dermatitis, eosinophilic
    esophagitis), drug reactions, malignancies, connective tissue
    disease, idiopathic hypereosinophilic syndrome, infections
    (helminths, Scarlet fever, Hansen's disease), sarcoidosis, SLE</p>
</li>
<li>
<p>Hypereosinophilia if AEC>1500, typically merits heme evaluation</p>
</li>
<li>
<p>Hypereosinophilic syndrome: AEC>1500 and organ dysfunction from
    eosinophils</p>
</li>
</ul>
<!-- -->

<ul>
<li>Basophilia (>100/mm<sup>3</sup>)</li>
</ul>
<!-- -->

<ul>
<li>CML, thyroid disease, IBC, chronic dermatitis, infections
    (varicella)</li>
</ul>
<p>Venous Thromboembolism – Kenna Koehler</p>
<p>Background</p>
<ul>
<li>
<p>Includes both deep vein thrombosis (DVTs) and pulmonary embolism
    (PE). See “Pulmonary Embolism” section in cardiology for more
    information on PEs</p>
</li>
<li>
<p>Risk Factors for Provoked DVT/PE</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Major risk factors: major surgery >30 minutes, hospitalization > 3
    days, C-section</p>
</li>
<li>
<p>Minor Risk Factors: Surgery \&lt;30 minutes, Hospitalization \&lt;3 days,
    pregnancy, estrogen therapy, reduced mobility >3 days</p>
</li>
</ul>
<!-- -->

<ul>
<li>Non-transient risk factors: Malignancy (active), IBD, liver disease,
    hereditary thrombophilia</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<p>Asymmetric calf swelling of >2cm sensitivity and specificity for
    DVT of 60-70%</p>
</li>
<li>
<p>Wells’ Criteria for DVT can help guide diagnostic testing</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>If a patient has a low pre-test probability, a negative D-dimer can
    rule out DVT</p>
</li>
<li>
<p>In a high pre-test probability patient a negative D-dimer is less
    helpful</p>
</li>
</ul>
<!-- -->

<ul>
<li>Whole-leg ultrasounds with doppler</li>
</ul>
<p>Management</p>
<ul>
<li>Prophylaxis: Padua score</li>
</ul>
<!-- -->

<ul>
<li>
<p>Score > 4 high risk, recommend pharmacologic prophylaxis</p>
<ul>
<li>Subcutaneous Low Molecular Weight Heparin (LMWH) or Subcutaneous
    Heparin</li>
</ul>
</li>
<li>
<p>Score \&lt;4 is low risk; recommend ambulation and SCDs</p>
</li>
</ul>
<!-- -->

<ul>
<li>Treatment (see anticoagulation section)</li>
</ul>
<!-- -->

<ul>
<li>
<p>Subcutaneous low molecular weight heparin (LMWH)</p>
</li>
<li>
<p>Oral factor Xa inhibitors (rivaroxaban, apixaban)</p>
</li>
<li>
<p>Intravenous unfractionated heparin</p>
</li>
<li>
<p>Warfarin (with bridge therapy)</p>
</li>
</ul>
<!-- -->

<ul>
<li>Duration of treatment</li>
</ul>
<!-- -->

<ul>
<li>
<p>Provoked: 3 months or until provoking factor (trauma, surgery,
    malignancy) is removed</p>
</li>
<li>
<p>Unprovoked: Typically requires life-long anticoagulation along with
    assistance from hematology</p>
</li>
</ul>
<!-- -->

<ul>
<li>Anticoagulation in malignancy:</li>
</ul>
<!-- -->

<ul>
<li>
<p>LMWH or DOAC (most evidence for apixaban and rivaroxaban) while
    malignancy still active</p>
</li>
<li>
<p>Avoid rivaroxaban and edoxaban in GI malignancies (increased rates
    of bleeding)</p>
</li>
</ul>
<p>Additional Information</p>
<ul>
<li>Should we get a follow up ultrasound?</li>
</ul>
<!-- -->

<ul>
<li>A follow up ultrasound at the CONCLUSION of anticoagulation can help
    establish a post-treatment baseline and provide a baseline study for
    future comparison that can be critical for the diagnosis of
    recurrent/new DVT (which is very difficult to determine
    radiographically without a comparison imaging study)</li>
</ul>
<!-- -->

<ul>
<li>What about IVC filters?</li>
</ul>
<!-- -->

<ul>
<li>Select circumstances for these: In patients with acute DVT or PE and
    in whom anti-coagulation is absolutely contraindicated
    (thrombocytopenia, recent intra-cranial bleed, recent GI bleed)
    placement of a retrievable IVC filter should be discussed with
    Hematology and IR</li>
</ul>
<p>Anticoagulation – Madeleine Turcotte</p>
<table>
<colgroup>
<col style="width: 22%" />
<col style="width: 18%" />
<col style="width: 18%" />
<col style="width: 18%" />
<col style="width: 21%" />
</colgroup>
<thead>
<tr class="header">
<th>Agent</th>
<th>Treatment Dose</th>
<th>Renal Dose</th>
<th>Prophylaxis</th>
<th>Monitoring</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Unfractionated heparin</td>
<td>80 U/kg bolus, then 18 U/kg/hr</td>
<td>No change necessary</td>
<td>5000 U q8h</td>
<td>PTT (automatic in order set)</td>
</tr>
<tr class="even">
<td><p>Enoxaparin</p>
<p>(Lovenox)</p></td>
<td>1 mg/kg q12h</td>
<td>1 mg/kg daily</td>
<td><p>40 mg daily</p>
<p>      or</p>
<p>30 mg BID</p></td>
<td><p>LMWH level (anti-Xa level)</p>
<p>Best checked 4 h after 4th dose</p>
<p> </p></td>
</tr>
<tr class="odd">
<td>Warfarin (Coumadin)</td>
<td><p>Start 2-5mg daily and monitor INR</p>
<p>Can consult Pharmacy</p>
<p> </p></td>
<td><p>No change</p>
<p>necessary</p></td>
<td>N/A</td>
<td><p>PT/INR</p>
<p>Use Chromogenic Factor X assay if pt has APLS</p></td>
</tr>
<tr class="even">
<td>Dabigatran (Pradaxa)</td>
<td><p>After 5 days of a parenteral AC,</p>
<p>150 mg BID</p></td>
<td>Avoid use</td>
<td>N/A</td>
<td><p>Can test drug level if concerned</p>
<p>(Any DOAC)</p></td>
</tr>
<tr class="odd">
<td>Rivaroxaban (Xarelto)</td>
<td>15 mg BID x21 d then 20 mg daily</td>
<td>Avoid use in CrCl&lt;30</td>
<td>10mg QD</td>
<td> </td>
</tr>
<tr class="even">
<td>Apixaban (Eliquis)</td>
<td>10mg BID x7d, then 5mg BID</td>
<td>VTE: No adjustment</td>
<td>2.5 mg BID</td>
<td><p>A Fib:</p>
<p>2.5mg BID, if 2 of the following:</p>
<p>Cr 1.5, Age &gt; 80</p>
<p>Weight &lt; 60kg</p></td>
</tr>
<tr class="odd">
<td>Edoxaban (Savaysa)</td>
<td><p>After 5 days of a parenteral AC,</p>
<p>60 mg daily</p></td>
<td><p>30 mg for</p>
<p>CrCl 15-50</p>
<p>Avoid if CrCl &gt; 95</p></td>
<td> </td>
<td>Best studied option in renal dysfunction</td>
</tr>
</tbody>
</table>

<p>Additional Information</p>
<ul>
<li>VA is starting to move towards rivaroxaban and apixaban for extended
    secondary thromboprophylaxis</li>
</ul>
<!-- -->

<ul>
<li>Write in your PADR for apixaban citing “patient uses a pillbox and
    cannot use dabigatran”</li>
</ul>
<!-- -->

<ul>
<li>
<p>Renal dysfunction: favor warfarin, apixaban or edoxaban</p>
</li>
<li>
<p>Hx of GI bleed: avoid dabigatran, rivaroxaban, edoxaban (may have
    higher risk of GI bleed)</p>
</li>
<li>
<p>Pregnancy: UFH/LMWH (other agents may cross the placenta)</p>
</li>
</ul>
<p>Transitioning Between Anticoagulants with DOACs</p>
<ul>
<li>LMWH to Warfarin</li>
</ul>
<!-- -->

<ul>
<li>Warfarin and LMWH given simultaneously until INR is therapeutic for
    24 hours</li>
</ul>
<!-- -->

<ul>
<li>Warfarin to DOAC</li>
</ul>
<!-- -->

<ul>
<li>Start DOAC when INR \&lt; 2.0</li>
</ul>
<!-- -->

<ul>
<li>DOAC to Warfarin</li>
</ul>
<!-- -->

<ul>
<li>
<p>High Risk DVT/PE – start LMWH or UFH, then start Warfarin</p>
</li>
<li>
<p>Low to Moderate Risk DVT/PE – Start warfarin while patient on DOAC,
    Stop DOAC on Day 3 of warfarin therapy, Check INR on day 4</p>
</li>
</ul>
<!-- -->

<ul>
<li>LMWH to DOAC</li>
</ul>
<!-- -->

<ul>
<li>Stop LMWH and start DOAC when due for next dose of LMWH (within 2
    hrs)</li>
</ul>
<!-- -->

<ul>
<li>DOAC to LMWH</li>
</ul>
<!-- -->

<ul>
<li>Stop DOAC and start LMWH when due for next DOAC dose</li>
</ul>
<!-- -->

<ul>
<li>UFH to DOAC</li>
</ul>
<!-- -->

<ul>
<li>
<p>Start DOAC when IV stopped (30 min prior to cessation if high risk
    for thrombosis)</p>
</li>
<li>
<p>DOAC to UFH</p>
</li>
<li>
<p>Start IV heparin with bolus when next DOAC dose is due</p>
</li>
</ul>
<p>Peri-Procedural Management of Anticoagulation</p>
<ul>
<li>
<p>Temporary IVC filter indicated in pts with very recent acute VTE
    (within 3-4 weeks) if the procedure requires AC delay >12 hours</p>
</li>
<li>
<p>For those at high risk of thromboembolism:</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Consider continuing AC for low-bleeding-risk procedures, i.e. dental
    procedures, cutaneous biopsy/excision, ICD placement, endovascular
    procedures.</p>
</li>
<li>
<p>Can bridge with LMWH or heparin drip</p>
</li>
</ul>
<table>
<colgroup>
<col style="width: 22%" />
<col style="width: 43%" />
<col style="width: 33%" />
</colgroup>
<thead>
<tr class="header">
<th></th>
<th>Stop before procedure</th>
<th>Restart after procedure</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Warfarin</td>
<td>5 days prior, check INR day of</td>
<td>12 to 24 hours after</td>
</tr>
<tr class="even">
<td>Dabigatran</td>
<td rowspan="4"><p>48 hours prior</p>
<p>(longer if CrCl 30-50 or procedure is high bleeding risk)</p></td>
<td rowspan="4"><p>1 day after</p>
<p>(2 days if high bleeding risk)</p></td>
</tr>
<tr class="odd">
<td>Rivaroxaban</td>
</tr>
<tr class="even">
<td>Apixaban</td>
</tr>
<tr class="odd">
<td>Edoxaban</td>
</tr>
<tr class="even">
<td>Heparin</td>
<td>Stop infusion 4-5 hours prior</td>
<td>24 hours after</td>
</tr>
<tr class="odd">
<td>Enoxaparin</td>
<td>12 - 24 hours prior</td>
<td>24 hours after, (48-72 hours if high bleeding risk)</td>
</tr>
</tbody>
</table>

<p>Strategies for Reversal of Anticoagulation</p>
<p>Warfarin</p>
<ul>
<li>Vitamin K: onset within a few hours but takes 24-48 hrs for full
    effect</li>
</ul>
<!-- -->

<ul>
<li>
<p>Life Threatening Bleeding: Give IV Vitamin K 10 mg over 30 minutes</p>
</li>
<li>
<p>Intracranial bleed, bleed with hemodynamic instability, emergent
    procedure non-life threatening</p>
<ul>
<li>
<p>INR \&lt;5: Vitamin K not recommended</p>
</li>
<li>
<p>INR 5-10: Vitamin K 1-5 mg IV or PO</p>
</li>
<li>
<p>INR >10: Vitamin K 5mg PO or 5 mg IV</p>
</li>
</ul>
</li>
<li>
<p>Prior to surgery</p>
<ul>
<li>Rapid reversal INR > 5: 5mg Vit K IV (24 hours prior to
    procedure)</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>FFP</li>
</ul>
<!-- -->

<ul>
<li>15 ml/kg (i.e. 4 units/70 kg person) if need reversal \&lt;24 hrs, plus
    give Vitamin K</li>
</ul>
<!-- -->

<ul>
<li>KCentra ($$$): Contains Factors II, VII, IX, and X with Protein C,
    Protein S, and heparin</li>
</ul>
<!-- -->

<ul>
<li>
<p>Given instead of plasma when insufficient time for plasma/Vit K to
    work (i.e. for life threatening hemorrhage)</p>
</li>
<li>
<p>Avoid giving this in HIT</p>
</li>
<li>
<p>Administer with Vitamin K</p>
</li>
</ul>
<p>Dabigatran</p>
<ul>
<li>Idarucizumab ($$$) will reverse if prolonged thrombin time (remember
    to check!) – Consult Hematology</li>
</ul>
<p>Factor Xa Inhibitors (rivaroxaban, apixaban, edoxaban)</p>
<ul>
<li>
<p>FEIBA (Factor VIII inhibitor bypassing activity) – can promote
    coagulation but is <u>not a reversal agent</u>; limited data to
    support use</p>
</li>
<li>
<p>Consult Hematology before using; andexanet alfa (FDA approved) is
    not on VUMC formulary but is on the VA formulary</p>
</li>
</ul>
<p>Hypercoagulable States – Chris Cann</p>
<p>Background</p>
<ul>
<li>
<p>Virchow’s triad: 1. Hypercoagulability 2. Stasis 3. Endothelial
    injury</p>
</li>
<li>
<p>Diagnostic thrombophilia testing indications:</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Idiopathic or recurrent VTE</p>
</li>
<li>
<p>First VTE at \&lt;40 years old</p>
</li>
<li>
<p>VTE in the setting of strong family history</p>
</li>
<li>
<p>VTE in unusual vascular site (cerebral, renal, mesenteric)</p>
</li>
<li>
<p>Recurrent pregnancy loss</p>
</li>
</ul>
<!-- -->

<ul>
<li>Must consider if thrombophilia testing will change clinical
    management</li>
</ul>
<!-- -->

<ul>
<li>
<p>If the unprovoked VTE warrants indefinite anticoagulation then
    testing may not be helpful</p>
</li>
<li>
<p>However, if VTE provoked by minor risk factor (OCPs) with an
    underlying thrombophilia might change the decision, then testing may
    be informative</p>
</li>
</ul>
<!-- -->

<ul>
<li>Separated into Acquired and Hereditary conditions:</li>
</ul>
<!-- -->

<ul>
<li>
<p>Hereditary: Factor V Leiden mutation, Prothrombin mutation, Protein
    C or S deficiency, Antithrombin deficiency</p>
</li>
<li>
<p>Acquired:</p>
<ul>
<li>
<p>Antiphospholipid Syndrome (APLS)</p>
</li>
<li>
<p>Heparin induced thrombocytopenia (HIT)</p>
</li>
<li>
<p>Major surgery/trauma</p>
</li>
<li>
<p>Nephrotic Syndrome</p>
</li>
<li>
<p>Smoking</p>
</li>
<li>
<p>Pregnancy</p>
</li>
<li>
<p>Oral Contraceptives</p>
</li>
<li>
<p>Immobilization (bedridden, hip/knee replacement)</p>
</li>
<li>
<p>Active malignancy</p>
</li>
<li>
<p>Estrogen replacement therapy</p>
</li>
<li>
<p>Note: Travel (plane, train, automobile) is NOT on this list and
    this is NOT considered a provoking risk factor</p>
</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Testing: all specific testing for hereditary disorders and APS
    should be performed at least 4-6 weeks after an acute thrombotic
    event or discontinuation of anticoagulant/thrombolytic therapies to
    avoid interference</li>
</ul>
<p>Antiphospholipid antibody syndrome (APLS)</p>
<p>Background</p>
<ul>
<li>
<p>Most common acquired disorder (anti-phospholipid antibodies present
    in 3-5% population)</p>
</li>
<li>
<p>Recurrent pregnancy loss, provoked DVT in young, unprovoked VTE and
    arterial thrombosis in young, thrombosis unusual sites, thrombosis
    in autoimmune disease</p>
</li>
<li>
<p>This is a clinicopathologic diagnosis (need both clinical and
    laboratory criteria)</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Positive for at least 1 lab criterion on at least 2 occasions, at
    least 12 weeks apart:</li>
</ul>
<!-- -->

<ul>
<li>
<p>Lupus anticoagulant: can occur in relation to drugs or infection;
    transient are associated with thrombotic risk</p>
</li>
<li>
<p>Anticardiolipin antibodies</p>
</li>
<li>
<p>B2GP1 (anti-beta2-glycoprotein) antibodies</p>
</li>
</ul>
<!-- -->

<ul>
<li>Must also meet at least 1 of the following clinical criteria:</li>
</ul>
<!-- -->

<ul>
<li>
<p>Vascular thrombosis: DVT, arterial thrombosis, or small vessel
    thrombosis of any organ</p>
</li>
<li>
<p>Pregnancy loss: there are specific criteria for this – consult
    UpToDate or other resource</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>Aspirin for primary prevention; warfarin for treatment (INR 2-3)</p>
</li>
<li>
<p>Do NOT use DOACs for triple positive APLS (see TRAPS trial:
    rivaroxaban inferior to warfarin)</p>
</li>
<li>
<p>Rituximab for recurrent thrombosis despite anticoagulation
    (controversial) – call hematology</p>
</li>
</ul>
<p>Heparin-induced thrombocytopenia (HIT)</p>
<p>Type 1: Mild and self-limited (not immune-mediated)</p>
<ul>
<li>
<p>Occurs within the first 2 days of first-time exposure</p>
</li>
<li>
<p>Platelet count normalizes with continued heparin therapy</p>
</li>
</ul>
<p>Type 2 (what we typically refer to as HIT): Immune mediated</p>
<ul>
<li>Fall in plt 30% to over 50% (even if plt count >150) and/or
    thrombotic event has occurred</li>
</ul>
<!-- -->

<ul>
<li>
<p>4-10 days after new exposure to heparin derivative OR≤</p>
</li>
<li>
<p>1 day after restarting heparin derivative that had been used 30-100
    days prior</p>
<ul>
<li>If exposed to heparin within 100 days, will have platelet drop
    within 24 hr</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Frequency: unfractionated heparin > LMWH; Surgical wards > medical
    wards</p>
</li>
<li>
<p>50% will have thrombotic event in 30 days if HIT is untreated, with
    20% mortality</p>
</li>
<li>
<p>Arterial thrombi are common in HIT</p>
</li>
<li>
<p>HIT results from antibodies to complexes of platelet factor 4 (PF4)
    and heparin, further activating platelets (the activated platelets
    aggregate causing thrombocytopenia)</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>4T score (0-8 points):</li>
</ul>
<!-- -->

<ul>
<li>
<p>Thrombocytopenia (0-2 pts): degree and nadir of platelet count drop</p>
</li>
<li>
<p>Timing (0-2 pts): timing of fall after initial or recurrent heparin
    exposure</p>
</li>
<li>
<p>Thrombosis (0-2 pts): thrombosis, skin necrosis, non-necrotizing
    lesions, acute systemic reaction to heparin</p>
</li>
<li>
<p>Other causes of thrombocytopenia (0-2 pts): more points if no
    alternate cause</p>
</li>
</ul>
<!-- -->

<ul>
<li>Solid-phase ELISA for heparin-PF4 antibodies:</li>
</ul>
<!-- -->

<ul>
<li>
<p>0.2-0.4 is indeterminate</p>
</li>
<li>
<p>> 0.4 is positive</p>
</li>
<li>
<p>> 1.4 HIT is likely</p>
</li>
<li>
<p>> 2 confirms HIT</p>
</li>
<li>
<p>The lab at VUMC will perform functional SRA reflexively for all
    values >0.2</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>0-3 points: Low concern for HIT; can restart heparin</p>
</li>
<li>
<p>4-5 points: Intermediate probability (~10%) - hold heparin, start
    non-heparin anticoagulant</p>
</li>
<li>
<p>6 points: High probability (~50%) - hold heparin, start non-heparin
    anticoagulant</p>
</li>
<li>
<p>Argatroban (direct thrombin inhibitor) for prophylaxis and treatment
    of thrombosis</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Avoid platelet transfusions as can increase thrombogenic effect</p>
</li>
<li>
<p>Avoid warfarin until complete platelet recovery as may cause
    microthrombosis</p>
</li>
</ul>
<!-- -->

<ul>
<li>Hematology consult for all confirmed HIT</li>
</ul>
<p>Factor V Leiden mutation</p>
<p>Evaluation</p>
<ul>
<li>Activated protein C resistance assay</li>
</ul>
<!-- -->

<ul>
<li>
<p>APC ratio in patient vs normal</p>
</li>
<li>
<p>normal >2.0, heterozygotes 1.5-2.0, homozygotes \&lt;1.5</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>FVL mutation is then determined via PCR</p>
</li>
<li>
<p>Screen with APC assay rather than PCR initially; cost effective</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>VTE treatment same as general population</li>
</ul>
<!-- -->

<ul>
<li>VTE 4-8x risk in heterozygotes; 80x risk in homozygotes</li>
</ul>
<!-- -->

<ul>
<li>Avoid OCPs: increased risk for VTE</li>
</ul>
<p>Prothrombin gene mutation</p>
<p>Evaluation:</p>
<ul>
<li>PCR of G20210A mutation (2-4% prevalence)</li>
</ul>
<p>Management:</p>
<ul>
<li>VTE treatment same as general population &amp; avoid OCPs</li>
</ul>
<p>Protein C &amp; S Deficiency</p>
<p>Background</p>
<ul>
<li>
<p>Autosomal dominant; first event occurs between 10-50 years of age</p>
</li>
<li>
<p>Synthesized in liver and Vit K dependent, therefore low levels in
    hepatic dysfunction and warfarin use/vitamin K deficiency</p>
</li>
<li>
<p>Protein C: low in settings of thrombosis, DIC, nephrotic syndrome,
    intra/post-op</p>
</li>
<li>
<p>Protein S: low in infectious (HIV) and autoimmune processes (IBD)</p>
</li>
<li>
<p>Protein S decreases during pregnancy (decreased free Protein S,
    normal total Protein S)</p>
</li>
</ul>
<!-- -->

<ul>
<li>Do not misdiagnose a pregnant patient with PS deficiency</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Functional Protein C &amp; S assays</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>VTE treatment same as general population</p>
</li>
<li>
<p>Avoid OCPs</p>
</li>
<li>
<p>High risk patients may require protein C concentrate prior to
    surgery</p>
</li>
<li>
<p>Increased risk of warfarin-induced skin necrosis</p>
</li>
</ul>
<p>Antithrombin deficiency</p>
<p>Background</p>
<ul>
<li>
<p>Autosomal dominant, does not skip generations</p>
</li>
<li>
<p>VTE in unusual sites (cerebral sinuses, renal veins)</p>
</li>
<li>
<p>Present \&lt; 50 y/o, but rarely in first two decades</p>
</li>
<li>
<p>Decreased in liver disease, nephrotic syndrome, protein losing
    enteropathy, burn, trauma, bypass surgery, metastatic tumors,
    premenopausal, OCP use, pregnancy</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<p>Functional antithrombin activity (AT-heparin cofactor assay)</p>
</li>
<li>
<p>Then perform antigen quantity testing</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>Can use Argatroban as does not require antithrombin function</p>
</li>
<li>
<p>Warfarin preferred in VTE (titrate up based on expression of
    antithrombin deficiency)</p>
</li>
</ul>
<p>Coagulopathies – Jason Jones</p>
<ul>
<li>
<p>Step one: determine if platelet vs coagulation disorder</p>
</li>
<li>
<p>Platelet Disorders: Skin/mucous membrane bleeding; Petechiae; Often
    mild bleeding following surgery and tends to immediately follow
    surgery</p>
</li>
<li>
<p>Coagulation defect: Bleeding deep in soft tissues (muscles/joints);
    hemarthroses, hematomas; tendency to have delayed bleeding after
    surgery that can be severe</p>
</li>
<li>
<p>Coagulopathies can be divided into Hereditary vs Acquired causes</p>
</li>
</ul>
<p>Hereditary</p>
<p>Hemophilia A (Factor VIII Deficiency) and Hemophilia B (Factor IX
Deficiency)</p>
<ul>
<li>
<p>Inherited in X-linked Recessive pattern</p>
</li>
<li>
<p>Diagnosis: Isolated prolonged PTT with normalization upon mixing
    study</p>
</li>
<li>
<p>Management: purified/recombinant Factor VIII or IX. Desmopressin for
    mild disease</p>
</li>
<li>
<p>Consult benign hematology every time these patients are admitted</p>
</li>
</ul>
<p>von Willebrand Disease (vWD)</p>
<ul>
<li>
<p>Can be hereditary (common) or acquired</p>
</li>
<li>
<p>Abnormal quantity or function of von Willebrand Factor (vWF) needed
    for platelet function</p>
</li>
<li>
<p>Type 1 (most common): Quantitative defect. Low quantity, normal
    function of vWF</p>
</li>
<li>
<p>Type 2: Qualitative defect. Normal quantity, abnormal function of
    vWF.</p>
</li>
<li>
<p>Type 3 (rare): Complete absence of vWF, phenotypically similar to
    hemophilia A</p>
</li>
<li>
<p>Order in Epic: vW Profile = vWF Ag, Factor VIII Activity, Ristocetin
    Cofactor Activity</p>
</li>
<li>
<p>Management: Desmopressin (DDAVP) can be useful as prophylaxis or
    treatment; most patients are treated with factor concentrate
    replacements</p>
</li>
</ul>
<p>Acquired</p>
<p>Coagulation Factor Inhibitors</p>
<ul>
<li>
<p>Associated with autoimmune disease (paraneoplastic vs. autoantibody)</p>
</li>
<li>
<p>Seen in hemophilia due to frequent treatments with recombinant
    factors (alloantibody)</p>
</li>
<li>
<p>Diagnosis: Elevated PTT that does not normalize with mixing study</p>
</li>
<li>
<p>Management: Immunosuppression with steroids; cyclophosphamide &plusmn;
    rituximab</p>
</li>
</ul>
<!-- -->

<ul>
<li>Consult Hematology always (rare disorder with major bleeding
    complications)</li>
</ul>
<p>Vitamin K Deficiency</p>
<ul>
<li>
<p>Caused by malnutrition, liver disease, or iatrogenic with warfarin</p>
</li>
<li>
<p>Diagnosis: elevated PT, if severe may have prolonged PTT as well</p>
</li>
<li>
<p>Management: Replace vitamin K</p>
</li>
</ul>
<p>Disseminated Intravascular Coagulation (DIC) - Eric Singhi</p>
<p>Background</p>
<ul>
<li>Concurrent activation of the coagulation pathway and fibrinolytic
    pathway</li>
</ul>
<!-- -->

<ul>
<li>Consumption of platelets, fibrin, and coagulation factors
    fibrinolysis end organ damage and hemolysis</li>
</ul>
<!-- -->

<ul>
<li>Etiologies:</li>
</ul>
<!-- -->

<ul>
<li>
<p>Infection/Sepsis, Liver disease, Pancreatitis, Trauma</p>
</li>
<li>
<p>Malignancies: mucin-secreting pancreatic/gastric adenocarcinoma,
    brain tumors, prostate cancer, all acute leukemias, acute
    promyelocytic leukemia</p>
</li>
<li>
<p>Obstetric complications (i.e. preeclampsia/eclampsia, placental
    abruption)</p>
</li>
<li>
<p>Acute hemolytic transfusion reaction (i.e. ABO incompatible
    transfusion)</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<p>Exam: petechiae, bleeding (mucosal, IV site, surgical wound site,
    hematuria), ecchymoses, thrombosis (i.e. cold, pulseless
    extremities)</p>
</li>
<li>
<p>CBC, PT/INR, aPTT, Fibrinogen, D-Dimer, Peripheral Blood Smear</p>
</li>
<li>
<p>“DIC labs” = q6h fibrinogen, PT/INR, aPTT (space out when lower
    risk)</p>
</li>
<li>
<p>Findings suggestive of DIC: thrombocytopenia, prolonged aPTT and
    PT/INR, hypofibrinogenemia, elevated D-dimer, fibrin degradation
    products, schistocytes</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>Treat the underlying cause!</p>
</li>
<li>
<p>Vitamin K for INR > 1.7 or bleeding</p>
</li>
<li>
<p>Hypofibrinogenemia treatment: Cryoprecipitate 5-10 units if
    fibrinogen \&lt; 100</p>
</li>
<li>
<p>Thrombocytopenia treatment: plt transfusion as normally indicated</p>
</li>
<li>
<p>DVT ppx if not bleeding and plt > 50</p>
</li>
<li>
<p>VTE: anticoagulation if plt > 50 and no massive bleeding</p>
</li>
</ul>
<p>Transfusion Medicine – R. Dixon Dorand</p>
<p>For emergent transfusions, call the blood bank (615-322-2233)</p>
<ul>
<li>
<p>RNs on 10T and 11N can follow transfusion protocols for pRBCs and
    Plts – enter as a Nursing Communication or as part of the
    Hematology/Oncology Admission Order set.</p>
</li>
<li>
<p>At VUMC, all special processing of blood products (such as
    irradiation) will be decided by blood bank based on special
    considerations listed in order set. Examples include: stem cell
    transplant, hematologic malignancy, or thalassemia</p>
</li>
<li>
<p>Patients with frequent transfusions (e.g. sickle cell
    hemoglobinopathy) should have an RBC Extended Phenotype ordered
    (once) for minor RBC antigens to avoid immunization and antibody
    development to these proteins</p>
</li>
<li>
<p>You may ask the VUMC hematology lab to email you pictures of the
    peripheral smear</p>
</li>
</ul>
<p>VA: Orders Tab – Blood Bank Orders – follow prompts to select
appropriate product. Must order both the blood product AND the
transfusion order (“Transfuse blood”)</p>
<ul>
<li>
<p>You need to specify all special processing such as irradiation</p>
</li>
<li>
<p>To order a Type &amp; Screen as a lab, you must go to Blood Bank Orders</p>
</li>
<li>
<p>Type &amp; Screen and Transfusion results are under the Blood tab in
    Results</p>
</li>
</ul>
<p>Red Blood Cell Transfusion</p>
<ul>
<li>
<p>Volume 200-300 mL per unit prbc</p>
</li>
<li>
<p>In general, 1 unit of packed RBCs increases Hgb by 1g/dL and HCT by
    ~3%</p>
</li>
<li>
<p>Assessment of the post-transfusion Hgb can be performed 15 min
    following transfusion, but ideally 1 hour after completion</p>
</li>
</ul>
<p>Indications:</p>
<ul>
<li>
<p>Hgb \&lt;9-10 g/dL – Acute coronary syndrome</p>
</li>
<li>
<p>Hgb \&lt;8 g/dL or Hct \&lt;25 – Bone marrow failure or receiving
    antineoplastic therapy</p>
</li>
</ul>
<!-- -->

<ul>
<li>Also sometimes used in pts with pre-existing CAD</li>
</ul>
<!-- -->

<ul>
<li>Hgb \&lt;7 g/dL or Hct \&lt;21 – ICU, GI Bleeding, Oncology patient on
    Treatment</li>
</ul>
<p>Indications for Platelets</p>
<ul>
<li>
<p>\&lt;11 k/µL – all patients, reduce risk of spontaneous hemorrhage (use
    on BMT, Brittingham)</p>
</li>
<li>
<p>\&lt;50 k/µL – active bleeding, scheduled to undergo select invasive
    procedure</p>
</li>
<li>
<p>\&lt;100 k/µL – CNS hemorrhage, intrathecal catheter</p>
</li>
</ul>
<!-- -->

<ul>
<li>This is also the threshold used for most Neurosurgical procedures</li>
</ul>
<p>Fresh Frozen Plasma (FFP) &amp; Cryoprecipitate (Cryo)</p>
<p>Cryoprecipitate</p>
<ul>
<li>FFP enriched for von Willebrand factor, factor VIII, factor XIII,
    and fibrinogen</li>
</ul>
<p>FFP</p>
<ul>
<li>
<p>Once thawed, must be used in 24 hrs (due to decline in labile
    coagulation factors)</p>
</li>
<li>
<p>Must be ABO compatible but not crossmatched or Rh typing</p>
</li>
<li>
<p>Only administer FFP if INR ≥1.7 (FFP will not fix an INR \&lt; 1.7)</p>
</li>
</ul>
<p>Indications for transfusion</p>
<ul>
<li>Bleeding:</li>
</ul>
<!-- -->

<ul>
<li>
<p>FFP If INR >1.7</p>
</li>
<li>
<p>Cryoprecipitate if fibrinogen \&lt;100.</p>
</li>
</ul>
<!-- -->

<ul>
<li>DIC:</li>
</ul>
<!-- -->

<ul>
<li>
<p>Fibrinogen \&lt;100: Transfuse 5 – 10 units cryoprecipitate and repeat
    fibrinogen. If bleeding, consider raising transfusion threshold of
    cryoprecipitate to fibrinogen \&lt;150</p>
</li>
<li>
<p>For elevated INR, consider FFP transfusion. Thresholds for doing
    this vary by attending</p>
</li>
</ul>
<!-- -->

<ul>
<li>Cirrhosis:</li>
</ul>
<!-- -->

<ul>
<li>
<p>General concept: PT/INR, aPTT are unreliable markers for bleeding.
    Fibrinogen ≤100 – 120 or thromboelastography are better surrogates
    for bleeding risk</p>
</li>
<li>
<p>Transfuse fibrinogen ≤100 – 120 if the patient is actively bleeding
    or about to undergo a procedure or surgery other than paracentesis</p>
</li>
<li>
<p>Transfuse FFP based on hepatology team preference (generally few
    indications for FFP)</p>
</li>
</ul>
<p>Transfusion Premedication &amp; Reactions</p>
<ul>
<li>
<p>If you are concerned about a serious transfusion reaction, pause the
    transfusion and contact the blood bank asap</p>
</li>
<li>
<p>Order the transfusion reaction blood testing in Epic. You will send
    a CBC, the bag of blood products, and the completed form to the
    blood bank for analysis</p>
</li>
</ul>
<p>Premedication:</p>
<ul>
<li>Only if history of severe reaction</li>
</ul>
<!-- -->

<ul>
<li>
<p>Diphenhydramine 25-50mg IV</p>
</li>
<li>
<p>Acetaminophen 650 mg PO</p>
</li>
<li>
<p>Meperidine 25-50 mg IV (optional for chills)</p>
</li>
<li>
<p>Hydrocortisone 50 mg IV (optional, for severe reactions or reactions
    despite acetaminophen and diphenhydramine)</p>
</li>
</ul>
<table>
<colgroup>
<col style="width: 19%" />
<col style="width: 26%" />
<col style="width: 27%" />
<col style="width: 26%" />
</colgroup>
<thead>
<tr class="header">
<th>Reaction</th>
<th>Signs &amp; Symptoms</th>
<th>Etiology</th>
<th>Clinical Action</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Allergic (mild)</td>
<td>Pruritus, hives limited to small area</td>
<td>Antibodies to transfused plasma proteins</td>
<td>Pause transfusion. Administer antihistamines. Resume transfusion if
improved; NO samples necessary. If no improvement in 30 min treat as
moderate to severe.</td>
</tr>
<tr class="even">
<td>Allergic<br />
(moderate<br />
to severe)</td>
<td>Generalized hives<br />
(&gt;2/3 body surface),<br />
bronchospasm &amp; dyspnea, abdominal pain, hypotension,<br />
nausea, anaphylaxis</td>
<td>Antibodies to<br />
transfused plasma<br />
proteins usually IgE but can also be IgA, Possible allergen in blood
product</td>
<td>Administer antihistamines, epinephrine, vasopressors and
corticosteroids as needed. Send product to blood bank.</td>
</tr>
<tr class="odd">
<td>Febrile Non-Hemolytic</td>
<td>Rise of temp &gt;1°C, chills, rigors, anxiety.</td>
<td>Cytokines released from residual white blood cells in the blood
product</td>
<td>Mild: administer antipyretics as needed</td>
</tr>
<tr class="even">
<td>Acute<br />
Hemolytic</td>
<td>Hemoglobinemia /<br />
uria, fever, chills,<br />
anxiety, shock,<br />
flank pain, chest<br />
pain, unexplained<br />
bleeding, cardiac<br />
arrest</td>
<td><p>Intravascular hemolysis usually due to ABO incompatibility;
Recheck for patient ID or clinical error.</p>
<p>This is an emergency.</p></td>
<td>Treat shock w/vasopressors; maintain airway; administer fluids and
maintain brisk diuresis; monitor for AKI.. Administer blood products as
needed after etiology is clear.</td>
</tr>
<tr class="odd">
<td>Septic</td>
<td>Rise of temp &gt; 2°C, sudden hypotension or hypertension,<br />
shock</td>
<td>Micro-organism (i.e. bacteria) in donor bag (Greater risk in
apheresis vs. RBC)</td>
<td>Send bag/tubing to transfusion medicine. Order BCx. Broad spectrum
abx  Pressor support if necessary.</td>
</tr>
<tr class="even">
<td>TRALI –<br />
Transfusion<br />
Related<br />
Acute Lung<br />
Injury</td>
<td>Acute respiratory<br />
distress usually<br />
within 1-2 hours<br />
of transfusion.<br />
Non-cardiogenic<br />
pulmonary edema<br />
unresponsive to<br />
diuretics; Dx of exclusion.</td>
<td>Usually donor HLA<br />
antibodies from<br />
transfused plasma. Recipient has corresponding<br />
antigens; causes neutrophil<br />
activation that<br />
results in<br />
extravasation of<br />
fluid into air<br />
spaces</td>
<td>Respiratory support! Most will resolve within 24-96 hours. Steroids,
diuretics: no known benefit.</td>
</tr>
</tbody>
</table>

<p>Sickle Cell Crisis – Michael J. Neuss</p>
<p>Background</p>
<ul>
<li>
<p>Present with severe pain in bone, joints, chest, abdomen</p>
</li>
<li>
<p>Causes: (HIDISC) Hypoxia, Ischemia, Dehydration, Infection, Stress,
    Cold</p>
</li>
<li>
<p>Can’t Miss:</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Acute chest: hypoxia + fever + chest pain + new infiltrate on CXR
    (consult benign hematology immediately, do not wait until the next
    day)</p>
</li>
<li>
<p>PE (ACS less likely in these patients); avascular necrosis of hip,
    priapism, stroke</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<p>Labs: LDH (high), Hgb/Hct (low; check vs baseline), retic, smear,
    WBC</p>
</li>
<li>
<p>If febrile: UA + Blood cultures</p>
</li>
<li>
<p>Send Hgb S level, and compare to baseline w/ other hospital
    admissions</p>
</li>
<li>
<p>Imaging: CXR, MRI for hip pain, Abdominal U/S or CT abdomen</p>
</li>
<li>
<p>Maintain active type and cross given probability of antibodies</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>General:</li>
</ul>
<!-- -->

<ul>
<li>
<p>Look for a care coordination yellow note in the Summary Tab</p>
<ul>
<li>Heme clinic will have specific management preferences for
    individual patients</li>
</ul>
</li>
<li>
<p>Maintain hydration, IVF at 150-200 cc/hr (if no contraindication)</p>
</li>
<li>
<p>Oxygen: goal sat ~95% (higher O2 goal will help to prevent further
    sickling!)</p>
</li>
<li>
<p>Continue folic acid 1 mg qDay</p>
</li>
<li>
<p>Continue hydroxyurea if uncomplicated pain crisis</p>
<ul>
<li>Hold if counts suppressed or concern for infection</li>
</ul>
</li>
<li>
<p>If in the MICU: consider discussion for plasma exchange (if Hgb SS
    or SC or S-Thal)</p>
</li>
<li>
<p>Transfuse: Simple transfusion if Hgb lower than baseline and/or
    complications</p>
<ul>
<li>Avoid transfusions when able, given risk of antibody formation</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Pain:</li>
</ul>
<!-- -->

<ul>
<li>
<p>Will generally require opiates, likely initiation of PCA</p>
</li>
<li>
<p>All SS patients should have pain plans; inpatient pain plans are in
    the problem list under sickle cell disease or in the care
    coordination section of Epic</p>
</li>
<li>
<p>Outpatient plans (to which you will transition pts back prior to
    discharge) are not standardized in location, but can be under Media
    (with a pain contract) or found in notes</p>
</li>
</ul>
<!-- -->

<ul>
<li>Acute chest:</li>
</ul>
<!-- -->

<ul>
<li>
<p>Consult Hematology at time of admission</p>
</li>
<li>
<p>D5 &frac12; NS @ 150-250 cc/hr</p>
</li>
<li>
<p>Transfuse hgb to >10</p>
</li>
<li>
<p>PCA w/ dilaudid</p>
</li>
<li>
<p>Abx for CAP (vs HAP if risk factors) ± bronchodilators</p>
</li>
</ul>
<p>Lymphoma – Danielle Fishman</p>
<p>Background</p>
<ul>
<li>
<p>Classically characterized by lymphadenopathy &amp; constitutional “B”
    symptoms: fevers, drenching night sweats and weight loss</p>
</li>
<li>
<p><strong>Hodgkin:</strong> 10% - superficial, nodal disease with orderly spread</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Bimodal Distribution: 15-35 years and >50 years; M>F</p>
</li>
<li>
<p>CD15+, CD30+ (Reed Sternberg cells “owl eyes”)</p>
</li>
<li>
<p>Associated with EBV in immunocompromised patient</p>
</li>
</ul>
<!-- -->

<ul>
<li><strong>Non-Hodgkin:</strong> 90% - diffuse, nodal and extranodal disease with
    noncontiguous spread</li>
</ul>
<!-- -->

<ul>
<li>
<p>Average 65 years, M>F, 85-90% B-cell</p>
</li>
<li>
<p>Associated with immunodeficiency (HIV, post-transplant), autoimmune
    disease, infection (EBV, HTLV-1, H pylori, HCV, Borrelia, C
    psittacosis, Coxiella)</p>
</li>
</ul>
<p>General Evaluation</p>
<ul>
<li>History</li>
</ul>
<!-- -->

<ul>
<li>B symptoms; pruritus (10-15% of pt with HL); history of radiation</li>
</ul>
<!-- -->

<ul>
<li>Physical Exam</li>
</ul>
<!-- -->

<ul>
<li>
<p>Head &amp; neck, tonsils, axilla, testes, liver, spleen</p>
</li>
<li>
<p>Lymphadenopathy: painless, firm, fixed, >1cm</p>
</li>
</ul>
<!-- -->

<ul>
<li>Lab tests:</li>
</ul>
<!-- -->

<ul>
<li>
<p>CBC, CMP, LDH, Uric Acid, Phosphorus</p>
</li>
<li>
<p>Consider HBV, HCV, HIV, EBV, Quant gold, Treponemal Ab, ANA</p>
</li>
</ul>
<!-- -->

<ul>
<li>Imaging:</li>
</ul>
<!-- -->

<ul>
<li>
<p>CT chest, abdomen, pelvis</p>
</li>
<li>
<p>Most will eventually need PET-CT; MRI brain if neuro symptoms</p>
</li>
</ul>
<!-- -->

<ul>
<li>Consider LP for NHL with high risk of CNS involvement or presence of
    neurological symptoms</li>
</ul>
<!-- -->

<ul>
<li>
<p>Risk factors: Burkitt, Lymphoblastic, testicular involvement,
    double/triple hit</p>
</li>
<li>
<p>Multiple LPs may be required to diagnose CNS lymphoma</p>
</li>
</ul>
<!-- -->

<ul>
<li>Diagnosis requires tissue</li>
</ul>
<!-- -->

<ul>
<li>
<p>Excisional Lymph node biopsy (Surg Onc Consult)</p>
</li>
<li>
<p>Core biopsy (CT guided procedure consult)</p>
</li>
<li>
<p>Of note, steroids may impact value of biopsy results</p>
</li>
</ul>
<!-- -->

<ul>
<li>Lugano Classification: staging of lymphoma</li>
</ul>
<!-- -->

<ul>
<li>
<p>I. 1 LN region or single extra lymphatic organ/site without nodal
    involvement</p>
</li>
<li>
<p>II. >2 LN regions, same side of diaphragm</p>
</li>
<li>
<p>III. LN regions on both sides of diaphragm</p>
</li>
<li>
<p>IV. Disseminated disease w/ 1+ extralymphatic organ</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p><strong>Hodgkin:</strong></p>
<ul>
<li>IPS negative prognostic calculator: albumin \&lt;4, hemoglobin
    &gt; \&lt;10.5, male, stage IV disease, age>45, WBC count> 15K,
    &gt; lymphocyte \&lt;8% of WBC count</li>
</ul>
</li>
<li>
<p><strong>Non-Hodgkin:</strong></p>
<ul>
<li>
<p><strong>Good prognosis:</strong> Follicular, Marginal Zone, Mycosis
    &gt; Fungoides/Sezary Syndrome</p>
</li>
<li>
<p><strong>Poor prognosis:</strong> DLBCL – can arise from low grade lymphoma
    &gt; (Richter transformation), Double**/**Triple Hit: bcl-2, bcl-6,
    &gt; or myc aberrations, Mantle Cell, Burkitt, Lymphoblastic
    &gt; Lymphoma, and Anaplastic Large Cell Lymphoma</p>
</li>
</ul>
</li>
</ul>
<p>General Management:</p>
<ul>
<li>
<p>ECG and TTE to establish pre-chemotherapy cardiac function – many
    chemo regimens with anthracyclines</p>
</li>
<li>
<p>Daily labs: CBC, TLS, LDH</p>
</li>
<li>
<p>TLS prophylaxis: mIVF, allopurinol</p>
</li>
</ul>
<p>Common Chemotherapy Regimens for Lymphoma</p>
<table>
<colgroup>
<col style="width: 25%" />
<col style="width: 50%" />
<col style="width: 25%" />
</colgroup>
<thead>
<tr class="header">
<th>Regimen</th>
<th>Components</th>
<th>Use</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>R-CHOP</td>
<td>Rituximab, cyclophosphamide, doxorubicin, vincristine,
prednisone</td>
<td>NHL</td>
</tr>
<tr class="even">
<td>R-EPOCH</td>
<td><p>Etoposide plus the drugs above</p>
<p>(dosing is different)</p></td>
<td><p>NHL</p>
<p>(Double/Triple hit)</p></td>
</tr>
<tr class="odd">
<td>Hyper-CVAD</td>
<td>Cyclophosphamide, vincristine, doxorubicin, and dexamethasone</td>
<td>NHL</td>
</tr>
<tr class="even">
<td>HD-MTX + R</td>
<td>High Dose methotrexate + Rituxumab</td>
<td>Primary CNS Lymphoma</td>
</tr>
<tr class="odd">
<td>ABVD</td>
<td>Doxorubicin, bleomycin, vinblastine, dacarbazine</td>
<td>HL</td>
</tr>
</tbody>
</table>

<p>Myelodysplastic Syndromes – Peter Hanna</p>
<p>Background</p>
<ul>
<li>
<p>MDS is a malignant clonal myeloid disorder resulting in ineffective
    (dysplastic) hematopoiesis leading to peripheral cytopenia’s and a
    risk of transformation to acute myeloid leukemia (AML)</p>
</li>
<li>
<p>Usually idiopathic, a disease of the elderly (median onset at age
    70)</p>
</li>
<li>
<p>The WHO has several classification schemes for MDS</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Most important for classification is the percent of blasts in the
    bone marrow</p>
</li>
<li>
<p>Note >20% blasts in marrow = AML. Thus MDS &amp; AML are on a continuum</p>
</li>
</ul>
<p>Presentation</p>
<ul>
<li>
<p>50% asymptomatic; Symptoms can include nonspecific but gradual
    fatigue, weakness</p>
</li>
<li>
<p>Dysplastic cells do not work properly infections and bleeding are
    more likely</p>
</li>
<li>
<p>Macrocytic anemia is most common finding; followed by bicytopenia or
    pancytopenia</p>
</li>
<li>
<p>Isolated neutropenia or thrombocytopenia are unusual but possible</p>
</li>
<li>
<p>Ask about secondary causes:</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Exposure to chemicals (benzene, crude oil/gasoline industry,
    cigarette smoke), chemotherapy, radiation</p>
</li>
<li>
<p>Medications, alcohol use, chronic infections (HIV)</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<p>Goal is to rule out reversible causes of dysplasia and cytopenias</p>
</li>
<li>
<p>CBC w/differential, Peripheral Smear, B12, Folate, HIV</p>
</li>
</ul>
<!-- -->

<ul>
<li>May consider Copper &amp; Zinc (send out labs, are expensive and rare
    but check when MDS is being considered)</li>
</ul>
<!-- -->

<ul>
<li>Dysplastic changes on peripheral smear: hypogranulated/hyposegmented
    neutrophils, hypogranulated platelets and macrocytosis of RBCs</li>
</ul>
<!-- -->

<ul>
<li>Circulating myeloblasts can be seen</li>
</ul>
<!-- -->

<ul>
<li>Final diagnosis made by Bone marrow Biopsy</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>Molecular characteristics define the “risk” of the disease and
    dictates treatments</p>
</li>
<li>
<p>Prognostic scoring tools: revised international prognostic staging
    system (R-IPSS)</p>
</li>
<li>
<p>Management general paradigm:</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Asymptomatic: with low-risk disease = monitoring</p>
</li>
<li>
<p>Low-risk disease + symptoms due to anemia only: transfusions,
    erythrocyte stimulating agents, and treatment with Luspatercept</p>
</li>
<li>
<p>MDS with isolated del(5q): treated with lenalidomide</p>
</li>
<li>
<p>High-risk patients: treated with hypomethylating agents</p>
</li>
<li>
<p>Only curative intervention = hematopoietic stem cell transplant
    (HSCT)</p>
</li>
</ul>
<p>Acute Leukemia – Robert Corty</p>
<p>Background</p>
<ul>
<li>
<p>Hematology malignant caused by unchecked proliferation of WBC
    precursors in the bone marrow</p>
</li>
<li>
<p>Pt’s with suspected acute leukemia require hospitalization for
    urgent diagnosis &amp; treatment</p>
</li>
<li>
<p>Types:</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>AML = Acute Myeloid Leukemia</p>
<ul>
<li>APL = Acute Promyelocytic Leukemia defined by translocation
    (15;17) PML-RARA</li>
</ul>
</li>
<li>
<p>ALL = Acute Lymphocytic Leukemia</p>
</li>
</ul>
<!-- -->

<ul>
<li>Risk Factors:</li>
</ul>
<!-- -->

<ul>
<li>
<p>radiation, chemical exposures (e.g benzene), chemotherapy (esp
    alkylating agents)</p>
</li>
<li>
<p>HIV, immunosuppression, smoking</p>
</li>
<li>
<p>myeloproliferative disorders, aplastic anemia</p>
</li>
</ul>
<p>Presentation</p>
<ul>
<li>
<p>Leukocytosis, leukemia cutis, gingival hypertrophy, leukostasis</p>
</li>
<li>
<p>Functional Leukopenia, often neutropenia: recurrent infections</p>
</li>
<li>
<p>Anemia: fatigue, pallor, dyspnea</p>
</li>
<li>
<p>Thrombocytopenia: gingival bleeding, epistaxis, petechiae,
    ecchymoses, menorrhagia</p>
</li>
<li>
<p>Extramedullary hematopoiesis: splenomegaly, hepatomegaly,
    lymphadenopathy</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Diagnosis of acute leukemia requires one of the following:</li>
</ul>
<!-- -->

<ul>
<li>
<p>20% blasts in peripheral blood</p>
</li>
<li>
<p>> 20% blasts in bone marrow biopsy</p>
</li>
<li>
<p>Any pathognomonic cytogenetic abnormality of t(8;21), inv(16),
    t(15;17)</p>
</li>
</ul>
<!-- -->

<ul>
<li>Check for the presence of these time-sensitive conditions.</li>
</ul>
<!-- -->

<ul>
<li>
<p>DIC – check fibrinogen, PT, PTT, platelets</p>
</li>
<li>
<p>TLS – check uric acid, phosphate, K+</p>
</li>
<li>
<p>Neutropenic fever – check temp, neutrophil count</p>
</li>
<li>
<p>Leukostasis (see below)</p>
</li>
<li>
<p>Presumptive APL – promyelocytes on diff, DIC or Auer rods on smear</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Confirm if peripheral flow cytometry ordered/in process</p>
</li>
<li>
<p>Use hematology admission order set</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Set RBC and Plt transfusion thresholds</p>
</li>
<li>
<p>Order nurse-driven electrolyte repletion</p>
</li>
<li>
<p>ECG and TTE to establish pre-chemotherapy cardiac function</p>
</li>
<li>
<p>Daily labs: CBC, TLS, DIC</p>
</li>
<li>
<p>TLS prophylaxis</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>Consult hematology</li>
</ul>
<!-- -->

<ul>
<li>
<p>Discuss chemo plan and order double lumen PICC for reliable access</p>
</li>
<li>
<p>If findings suggest APL start ATRA</p>
</li>
<li>
<p>Subspecialized lab tests: bone marrow biopsy, cytogenetics, FISH</p>
</li>
</ul>
<!-- -->

<ul>
<li>Monitor for Common Complications/Emergencies: (see individual
    sections)</li>
</ul>
<!-- -->

<ul>
<li>TLS, DIC, Febrile Neutropenia, Leukostasis</li>
</ul>
<p>Additional Information</p>
<ul>
<li>
<p>Obtain blood product consent on admission</p>
</li>
<li>
<p>APL Specific findings: promyelocytes on differential or Auer rods on
    smear</p>
</li>
<li>
<p>Differentiation syndrome: promyelocytes differentiate</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Symptoms and signs: fever, SOB, Hypotn, peripheral edema, pleural
    effusion, AKI</p>
</li>
<li>
<p>Diagnosis: No defined criteria. If suspicious, discuss with
    hematology fellow</p>
</li>
<li>
<p>Management: steroids. If critically ill, hold ATRA and ATO and
    consider hydroxyurea</p>
</li>
</ul>
<p>Leukemia Treatment Overview</p>
<ul>
<li>
<p>General strategy is to use “induction” chemo to try to induce
    clinicopathologic (as opposed to molecular) “remission”</p>
</li>
<li>
<p>Defined as absence of symptoms, normal CBC, and \&lt; 5% blasts in bone
    marrow (on day 28)</p>
</li>
<li>
<p>Then waiting in hospital until neutrophil count > 500 (typically
    ~3 weeks)</p>
</li>
<li>
<p>From there, bone marrow transplant (for high-risk disease) or
    “consolidation” chemo for normal-risk or low-risk disease</p>
</li>
</ul>
<p>AML</p>
<ul>
<li>Induction</li>
</ul>
<!-- -->

<ul>
<li>
<p>Typical is “7+3” i.e. idrarubicin on days 1-3 and cytarabine on days
    1-7</p>
</li>
<li>
<p>If therapy-related AML, MDS-related AML, or AML with cytogenetics
    similar to MDS, use “Vyxeos” which is liposomal daunorubicin and
    cytarabine on days 1, 3, and 5</p>
</li>
<li>
<p>If low-risk dz (t(8;21) or inv(16)), use cytarabine on days 1-7, and
    3 days of low-dose daunorubicin + gemtuzumab-ozogamicin</p>
</li>
<li>
<p>There are other induction regimens that can be used depending on
    specific cytogenetics and patient frailty, which is beyond the scope
    of the handbook</p>
</li>
</ul>
<!-- -->

<ul>
<li>Consolidation</li>
</ul>
<!-- -->

<ul>
<li>
<p>Typically “HiDAC”(high-dose Ara-C i.e. cytarabine)</p>
<ul>
<li>Generally too toxic for pts with age > 60, so a dose reduction
    is used</li>
</ul>
</li>
<li>
<p>In the case of relapse, typical treatment is a different high-dose
    chemo and BMT if possible</p>
</li>
</ul>
<p>ALL</p>
<ul>
<li>
<p>Typical induction is “HyperCVAD” (hyper-fractionated
    cyclophosphamide, vincristine, doxorubicin (“A” due to trade name
    Adriamycin), and dexamethasone</p>
</li>
<li>
<p>If t(9;22) (known as Philadelphia chromosome), use tyrosine kinase
    inhibitor (TKI)</p>
</li>
<li>
<p>If CD20+, use rituximab</p>
</li>
</ul>
<p>Common Chemotherapy Regimens for Leukemia Encountered as Inpatient</p>
<table>
<colgroup>
<col style="width: 22%" />
<col style="width: 48%" />
<col style="width: 29%" />
</colgroup>
<thead>
<tr class="header">
<th>Regimen</th>
<th>Components</th>
<th>Use</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><p>7+3</p>
<p> </p></td>
<td>Cytarabine (Ara-C) x 7 d &amp; Anthracycline  (e.g. idarubicin x3
d)</td>
<td>AML induction</td>
</tr>
<tr class="even">
<td>Vyxeos</td>
<td>Cytarabine + liposomal daunorubicin</td>
<td>AML-MRC or t-AML</td>
</tr>
<tr class="odd">
<td>CLAG-M</td>
<td>Cladribine, cytarabine (Ara-C), Filgrastim (G-CSF),
mitoxantrone</td>
<td>AML induction (relapsed/refractory)</td>
</tr>
<tr class="even">
<td>HIDAC</td>
<td>High-dose cytarabine</td>
<td>AML consolidation</td>
</tr>
<tr class="odd">
<td>ATRA</td>
<td><p>All-trans retinoic acid</p>
<p>given with arsenic trioxide (ATO)</p></td>
<td>APL (APML)</td>
</tr>
<tr class="even">
<td>HyperCVAD/MA</td>
<td><p>CVAD = Cyclophosphamide, vincristine, doxorubicin,
dexamethasone</p>
<p>MA = methotrexate/cytarabine </p>
<p>(Given as alternating cycles)</p></td>
<td>ALL</td>
</tr>
<tr class="odd">
<td>R-CHOP</td>
<td>Rituximab, cyclophosphamide, doxorubicin, vincristine,
prednisone</td>
<td>NHL</td>
</tr>
<tr class="even">
<td>R-EPOCH</td>
<td><p>Etoposide plus the drugs above</p>
<p>(dosing is different)</p></td>
<td>NHL</td>
</tr>
<tr class="odd">
<td>ABVD</td>
<td>Doxorubicin, bleomycin, vinblastine, dacarbazine</td>
<td>HL</td>
</tr>
</tbody>
</table>

<p>Plasma Cell Dyscrasias – Rahul Shah, Jennifer Marvin-Peek</p>
<p>Background</p>
<ul>
<li>
<p>A heterogenous group of benign, premalignant, and malignant
    conditions characterized by clonal proliferation of plasma cells</p>
</li>
<li>
<p>Results in over-production of monoclonal immunoglobulins or
    polypeptides (i.e., M-protein) that can be detected in serum and/or
    urine</p>
</li>
<li>
<p>Includes monoclonal gammopathy of undetermined significance (MGUS),
    smoldering myeloma (SMM), multiple myeloma (MM), Waldenström
    Macroglobulinemia (WM), extra-medullary plasmacytoma, AL
    amyloidosis, POEMS syndrome</p>
</li>
<li>
<p>Spectrum of MGUS, SMM, and MM represents natural progression of same
    disease process</p>
</li>
<li>
<p>Complications: Increased infectious risk, cytopenias, renal failure,
    hyperviscosity syndrome, malignant hypercalcemia, pain crisis from
    bony disease</p>
</li>
<li>
<p>Elevated gamma/protein gap (serum total protein minus albumin >4)
    often prompts work-up for an underlying plasma cell dyscrasia (high
    specificity but low sensitivity)</p>
</li>
</ul>
<table>
<colgroup>
<col style="width: 48%" />
<col style="width: 51%" />
</colgroup>
<thead>
<tr class="header">
<th>Symptoms</th>
<th>Signs</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><p>Fatigue, weakness, weight loss</p>
<p>Bone pain</p>
<p>Paresthesias, neuropathy, radiculopathy</p>
<p>Visual disturbances</p>
<p>(if hyperviscosity present)</p>
<p>Lymphadenopathy (uncommon)</p>
<p>Fever (uncommon)</p></td>
<td><p>Anemia (Hgb &lt;10)</p>
<p>Renal insufficiency (Cr &gt; 2)</p>
<p>Hypercalcemia (Ca &gt; 11.5)</p>
<p>Elevated protein gap (Total protein - Alb &gt; 4)</p>
<p>Osteolytic bone lesions (typically central)</p>
<p>Unexplained heavy proteinuria</p>
<p>Rouleaux formation on blood smear</p></td>
</tr>
</tbody>
</table>

<p>Evaluation</p>
<ul>
<li>
<p>CBC w/ diff, peripheral blood smear, CMP (for Ca, Cr, albumin), LDH,
    CRP, urinalysis</p>
</li>
<li>
<p>SPEP with immunofixation, UPEP (24-hour urine) with immunofixation,
    serum free light chains (FLC)</p>
</li>
<li>
<p>Quantitative immunoglobulins (IgA, IgM, IgG, IgD, IgE)</p>
</li>
<li>
<p>If Hgb \&lt;10, Cr >2, Ca >11.5, M-protein >1.5, non-IgG M-spike,
    abnormal FLC ratio:</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Bone marrow biopsy + cytogenetics</p>
</li>
<li>
<p>β2-microglobulin, serum viscosity (in WM)</p>
</li>
<li>
<p>Skeletal imaging to identify bone lesions: skeletal survey (x-ray)
    often done initially, then more sensitive CT/PET-CT/MRI if biopsy
    shows SMM/MM</p>
</li>
<li>
<p>If considering amyloidosis: abdominal wall fat pad biopsy with Congo
    red staining typically sufficient vs direct biopsy of
    amyloid-involved tissue</p>
</li>
</ul>
<table>
<colgroup>
<col style="width: 33%" />
<col style="width: 33%" />
<col style="width: 32%" />
</colgroup>
<thead>
<tr class="header">
<th colspan="3">Additional Tips for Lab Interpretation</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>SPEP/UPEP</td>
<td>Free light chains (FLC)</td>
<td>Urinalysis</td>
</tr>
<tr class="even">
<td><p>Initial screening test to look and quantify M-protein</p>
<p>Serum immunofixation determines clonality</p>
<p>(e.g. mono or polyclonal)</p>
<p> </p>
<p>Monoclonal spike &gt;1.5 is indicative of underlying dyscrasia</p>
<p> </p>
<p>Polyclonal spike suggests infectious, inflammatory, or reactive
etiology</p></td>
<td><p>Ratio of kappa/lambda &gt;3 highly suggestive of plasma cell
dyscrasia or amyloidosis</p>
<p> </p>
<p>Ratio 1.65 to 3 can be due to infectious process or renal
insufficiency</p>
<p> </p>
<p>Helpful in pts that only produce Bence-Jones protein (FLC w/o heavy
chain) which isn't seen on SPEP</p></td>
<td><p>Detects albumin, not light chains</p>
<p> </p>
<p>In myeloma cast nephropathy, dipstick will be negative since
proteinuria is from FLC (i.e. Bence-Jones proteinuria)</p>
<p> </p>
<p>In AL amyloid, dipstick will be positive 2/2 albumin loss from
nephrotic syndrome</p></td>
</tr>
</tbody>
</table>

<table>
<colgroup>
<col style="width: 25%" />
<col style="width: 25%" />
<col style="width: 22%" />
<col style="width: 27%" />
</colgroup>
<thead>
<tr class="header">
<th></th>
<th><p>Monoclonal Gammopathy of Unknown Significance</p>
<p>(MGUS)</p></th>
<th><p>Smoldering Multiple Myeloma</p>
<p>(SMM)</p></th>
<th><p>Multiple Myeloma</p>
<p>(MM)</p></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>% Plasma Cells in BM</td>
<td>&lt;10%</td>
<td>10-60%</td>
<td>≥ 10% (typically &gt;30%)</td>
</tr>
<tr class="even">
<td>Monoclonal Protein</td>
<td>IgG, IgA, IgM: 1.5 -3</td>
<td>IgG or IgA &gt;3</td>
<td>IgG or IgA &gt;3</td>
</tr>
<tr class="odd">
<td>Laboratory studies</td>
<td>Normal Hgb, Ca, Cr</td>
<td>Normal Hgb, Ca, Cr</td>
<td>↓Hgb, ↑Ca, ↑Cr</td>
</tr>
<tr class="even">
<td>Symptoms</td>
<td>None</td>
<td>None</td>
<td>Lytic bone lesions, fatigue</td>
</tr>
<tr class="odd">
<td>Prognosis</td>
<td>1% / year progression to MM</td>
<td>10% / year progression to MM</td>
<td>R-ISS staging (see below)</td>
</tr>
<tr class="even">
<td>Monitoring and/or Treatment</td>
<td><p>Monitoring only</p>
<p>Yearly:</p>
<p>Symptom check</p>
<p>SPEP, FLC, CBC, BMP</p></td>
<td><p>Monitoring only</p>
<p>In 2-3 months, repeat SPEP, FLC, CBC, BMP</p>
<p>Yearly skeletal survey</p></td>
<td>Chemotherapy, plus SCT for eligible patients</td>
</tr>
</tbody>
</table>

<p>Multiple Myeloma</p>
<p>Evaluation</p>
<ul>
<li>
<p>Diagnosis requires clonal bone marrow plasma cells ≥10% or
    bony/extramedullary plasmacytoma AND one or more end-organ event
    (CRAB criteria) or biomarker of myeloma</p>
</li>
<li>
<p>CRAB criteria</p>
<ul>
<li>Hypercalcemia, renal impairment, anemia, bone osteolytic lesions</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Biomarkers of multiple myeloma</p>
<ul>
<li>
<p>Clonal bone marrow plasma cells ≥ 60%</p>
</li>
<li>
<p>Serum FLC ratio ≥ 100 or ≤ 0.01</p>
</li>
<li>
<p>>1 focal lesion ≥ 5mm on MRI</p>
</li>
</ul>
</li>
<li>
<p>Skeletal imaging: Whole-body PET-CT or CT preferred, MRI, bone
    survey (x-ray)</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>First-line induction therapy typically is RVd: immunomodulatory
    agent (lenalidomide [<u>R</u>evlimid]), proteasome inhibitor
    (bortezomib [<u>V</u>elcade]) and <u>d</u>examethasone</p>
</li>
<li>
<p>Consolidation therapy includes autologous SCT for transplant
    eligible patients</p>
</li>
<li>
<p>Maintenance therapy is often given indefinitely, typically
    lenalidomide or bortezomib</p>
</li>
<li>
<p>Relapsed disease is often treated with anti-CD38 monoclonal Ab
    (daratumumab) with a steroid and either immunomodulatory drug or
    proteosome inhibitor; CAR-T also recently approved for relapsed MM</p>
</li>
<li>
<p>Supportive Care</p>
</li>
</ul>
<!-- -->

<ul>
<li>VTE prophylaxis with DOAC or LMWH if on an immunomodulatory agent
    &gt; with 2 VTE risk factors; if only 0-1 VTE risk factors aspirin</li>
</ul>
<!-- -->

<ul>
<li>
<p>EPO and G-CSF for treatment-related anemia and neutropenia</p>
</li>
<li>
<p>Bisphosphonate (ideally zoledronic acid) to reduce risk of
    &gt; fractures; analgesia ± radiotherapy for bone pain and palliation</p>
</li>
<li>
<p>(Val)acyclovir if on bortezomib for VZV prophylaxis</p>
</li>
</ul>
<p>Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia (IgM)</p>
<p>Presentation</p>
<ul>
<li>
<p>Hyperviscosity syndrome: blurred vision, dizziness, diplopia,
    hypoxia, ataxia, vertigo, stroke, coma</p>
</li>
<li>
<p>Peripheral neuropathy</p>
</li>
<li>
<p>Retinal changes: dilated veins, hemorrhages, papilledema</p>
</li>
<li>
<p>Cryoglobulinemia: large IgM complexes precipitate out in the cold,
    causing Raynaud's, urticaria, purpura, acral cyanosis, tissue
    necrosis</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<p>Requires: IgM monoclonal gammopathy on SPEP, BM biopsy w/≥10%
    lymphocytes with plasmacytoid differentiation (late stage B-cell
    differentiation), and MYD88 mutation detected</p>
</li>
<li>
<p>CBC, coagulation studies, cryoglobulins, IgM, β2-microglobulin</p>
</li>
<li>
<p>Serum viscosity (If \&lt;4 symptoms are rare, If >6 typically
    symptomatic)</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>Asymptomatic patients managed with close observation</p>
</li>
<li>
<p>Symptomatic hyperviscosity is treated with plasmapheresis</p>
</li>
<li>
<p>Induction: may include bendamustine &plusmn; rituximab if IgM level is
    \&lt;4000 (Rituximab can temporarily ↑ IgM and ↑ risk of hyperviscosity
    syndrome)</p>
</li>
<li>
<p>Monitor response with: IgM levels, monoclonal IgM on SPEP</p>
</li>
</ul>
<p>Other Plasma Cell Dyscrasias</p>
<p>Light Chain (AL) Amyloidosis</p>
<ul>
<li>Extracellular deposition of misfolded light chains (most commonly
    kidney &amp; heart)</li>
</ul>
<!-- -->

<ul>
<li>Features: nephrotic syndrome, restrictive CM, peripheral neuropathy,
    &gt; HSM, macroglossia, easy bruising/bleeding,
    &gt; dysautonomia/orthostasis</li>
</ul>
<!-- -->

<ul>
<li>
<p>Diagnosis:</p>
<ul>
<li>Need ALL 4: amyloid related systemic syndrome, positive congo
    &gt; red staining on any tissue, evidence that amyloid is light
    &gt; chain related, evidence of monoclonal plasma cell disorder</li>
</ul>
</li>
</ul>
<p>POEMS Syndrome</p>
<ul>
<li>
<p>Cause unknown, possibly chronic overproduction of pro-inflammatory
    cytokines such as VEGF</p>
</li>
<li>
<p>Features: Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal
    protein (usually λ light chain), Skin changes</p>
</li>
<li>
<p>Diagnosis:</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Mandatory Criteria: peripheral neuropathy, monoclonal plasma cell
    disorder</p>
</li>
<li>
<p>Major Criteria (need &#8531;): osteosclerotic lesions, VEGF, Castleman
    disease</p>
</li>
<li>
<p>Minor Criteria (need &#8537;): organomegaly, volume overload,
    endocrinopathy, skin changes, papilledema, thrombocytosis or
    polycythemia</p>
</li>
</ul>
<p>Castleman Disease</p>
<ul>
<li>
<p>Angiofollicular lymph node hyperplasia</p>
</li>
<li>
<p>Antibodies to HHV-8 implicated in >50% of cases</p>
</li>
<li>
<p>Features: Lymphadenopathy, fever, night sweats, fatigue, fluid
    accumulation, violaceous lymph node biopsy w/characteristic
    hematopathology papules</p>
</li>
</ul>
<p>Myeloproliferative Neoplasms (MPNs) – Christina Snider</p>
<p>Background</p>
<ul>
<li>
<p>MPNs = chronic myeloid disorders caused by abnormal proliferation of
    mature bone marrow cell lineages (granulocytes, erythrocytes, or
    megakaryocytes)</p>
</li>
<li>
<p>MPNs differ from myelodysplastic syndrome (MDS); cells in MPNs are
    normally developed (i.e. not dysplastic)</p>
</li>
<li>
<p>Four “classic” MPNs: polycythemia vera, essential thrombocythemia,
    primary myelofibrosis and chronic myeloid leukemia (CML)</p>
</li>
</ul>
<p>Polycythemia Vera (PV)</p>
<p>Background</p>
<ul>
<li>
<p>Polycythemia is a general term: Men = Hb/Hct > 16.5/49%; Women =
    Hb/Hct > 16/48%</p>
</li>
<li>
<p>Relative polycythemia = Concentrated H/H due to decreased plasma
    volume</p>
</li>
</ul>
<!-- -->

<ul>
<li>Diuretic use, vomiting, diarrhea; H/H should normalize with fluid
    resuscitation</li>
</ul>
<!-- -->

<ul>
<li>Absolute polycythemia = Increased RBC mass</li>
</ul>
<!-- -->

<ul>
<li>
<p>Primary polycythemia: 2/2 Inherited/acquired mutation in RBC
    progenitor</p>
</li>
<li>
<p>Secondary polycythemia: Increase in RBC mass due to elevated serum
    EPO</p>
<ul>
<li>
<p>Hypoxia/cardiopulmonary associated (chronic pulmonary disease,
    R-to-L cardiac shunts, sleep apnea, obesity hypoventilation
    syndrome, chronic carbon monoxide poisoning, including heavy
    smoking)</p>
</li>
<li>
<p>Kidney associated causes (following renal transplant, renal
    artery stenosis, hydronephrosis)</p>
</li>
<li>
<p>Autonomous EPO production from an EPO-producing tumors (rare)</p>
</li>
<li>
<p>Steroid Use</p>
</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Epidemiology: Median age of diagnosis is 60 years; 25% cases present
    at age \&lt;50 years.</p>
</li>
<li>
<p>>95% PV pts have JAK2 V617F mutation, but JAK2 V617F mutation is
    not specific to PV and can be seen in other MPNs</p>
</li>
</ul>
<p>Presentation</p>
<ul>
<li>
<p>Incidentally elevated H/H</p>
</li>
<li>
<p>Splenomegaly, generalized pruritus (post-warm bath/shower), unusual
    thrombosis</p>
</li>
<li>
<p>Erythromelalgia: intermittent occurrence of red, hot, painful
    extremities</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<p>CBC with differential and peripheral smear</p>
</li>
<li>
<p>EPO level</p>
</li>
<li>
<p>Rule out secondary causes: Sleep Study, Carboxyhemoglobin, steroids</p>
</li>
<li>
<p>Peripheral blood screen for JAK2 V617F mutation</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>PV treatment aims to prevent thrombosis and bleeding events.</p>
</li>
<li>
<p>Phlebotomy: maintain Hct \&lt;45% (One unit 500 mL decreases Hct by 3%)</p>
</li>
<li>
<p>ASA 81 mg for thrombosis prevention and symptom control</p>
</li>
<li>
<p>Hydroxyurea: indicated for high-risk patients (>60 years old or
    with history of thrombosis)</p>
</li>
<li>
<p>Interferon-alfa, busulfan, or ruxolitinib: indicated in select
    high-risk patients</p>
</li>
</ul>
<p>Essential thrombocythemia (ET)</p>
<p>Background</p>
<ul>
<li>
<p>Clonal stem cell disorder w/ increased platelet counts (>450k/uL)</p>
</li>
<li>
<p>Risks of thrombosis and hemorrhage</p>
</li>
<li>
<p>Median age of diagnosis: 60 years; Twice as common in females.</p>
</li>
</ul>
<p>Presentation</p>
<ul>
<li>
<p>Incidental thrombocytosis on CBC</p>
</li>
<li>
<p>Splenomegaly, unusual thrombosis, and erythromelalgia</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<p>Screen for conditions that cause reactive thrombocytosis: Chronic
    inflammatory diseases, infections, bleeding/hemolysis, iron
    deficiency, post splenectomy</p>
</li>
<li>
<p>CBC with smear (platelet anisocytosis) ranging from very small to
    giant platelets</p>
</li>
<li>
<p>CMP, LDH, Uric Acid, iron studies</p>
</li>
<li>
<p>BCR ABL1 testing should be sent to exclude CML</p>
</li>
<li>
<p>Bone marrow biopsy with staining, cytogenetics, and molecular
    testing for JAK2, CALR, MPL mutations</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>Avoid ASA 81 in patients with platelet counts >1 million
    complicated by acquired von Willebrand syndrome due to increased
    risk of bleeding</li>
</ul>
<table>
<colgroup>
<col style="width: 35%" />
<col style="width: 29%" />
<col style="width: 35%" />
</colgroup>
<thead>
<tr class="header">
<th colspan="3">Treatment of ET</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><p><strong> Risk Score</strong></p>
<p><strong>(IPSET-thrombosis)</strong></p></td>
<td><strong>Features</strong></td>
<td><strong>Treatment</strong></td>
</tr>
<tr class="even">
<td>High</td>
<td>Hx of thrombosis and/or &gt;age 60 with JAK2 V617F mutation</td>
<td rowspan="2">Cytoreduction (target plt 100-400k) w/ hydroxyurea,
systemic anticoagulation +/-antiplatelet agent</td>
</tr>
<tr class="odd">
<td>Intermediate</td>
<td>Age &gt;60, no JAK2 V617F mutation, no history of thrombosis</td>
</tr>
<tr class="even">
<td>Low</td>
<td>Age =&lt;60 w/ JAK2 V617F mutation and no history of thrombosis</td>
<td rowspan="2"><p>Observation vs. daily ASA 81</p>
<p> </p></td>
</tr>
<tr class="odd">
<td>Very Low</td>
<td>Age =&lt;60, no JAK2 V617F mutation, no history of thrombosis</td>
</tr>
</tbody>
</table>

<p>Primary Myelofibrosis (PMF)</p>
<p>Background</p>
<ul>
<li>
<p>Clonal proliferation of myeloid cells with variable morphologic
    maturity resulting in reactive marrow fibrosis and extramedullary
    hematopoiesis</p>
</li>
<li>
<p>Least favorable prognosis out of MPN</p>
</li>
</ul>
<p>Presentation</p>
<ul>
<li>
<p>Fatigue, weight loss, low grade fever, bone pain, and night sweats</p>
</li>
<li>
<p>Marked splenomegaly &plusmn;hepatomegaly (due to extramedullary
    hematopoiesis)</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<p>smear: teardrop shaped RBCs (dacrocytes)</p>
</li>
<li>
<p>Bone marrow biopsy: “dry tap” due to extensive reticulin and/or
    collagen fibrosis mutually exclusive mutations in JAK2, MPL, or CALR</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>Low risk patients: Observe if asymptomatic</p>
</li>
<li>
<p>Cure by allogenic HCT transplantation in young, high-risk patients</p>
</li>
<li>
<p>Treatment of anemias include transfusion support</p>
</li>
<li>
<p>Surgical splenectomy if abdominal pain or transfusion dependent
    anemia (used very infrequently)</p>
</li>
</ul>
<p>Chronic Myelogenous Leukemia (CML)</p>
<p>Background</p>
<ul>
<li>
<p>Definition: MPN characterized by the overproduction of myeloid stem
    cells that can differentiate</p>
</li>
<li>
<p>Chronic phase:</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Fatigue, weight loss, bleeding</p>
</li>
<li>
<p>Abdominal fullness and early satiety due to splenomegaly</p>
</li>
<li>
<p>WBC on CBC is typically >100k, and smear shows neutrophilic cells
    in all stages of maturation with \&lt;2% blasts</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Accelerated phase: Refractory leukocytosis, 10-19% blasts in
    peripheral blood or bone marrow, worsening peripheral basophilia,
    thrombocytopenia</p>
</li>
<li>
<p>Blast phase = acute leukemia. >20% blasts in peripheral blood or
    bone marrow, extramedullary proliferation of blasts</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Typical findings in blood and bone marrow and confirmation of
    Philadelphia chromosome (BCR-ABL1 fusion gene) via conventional
    cytogenetics, FISH, or rt-PCR</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>Hydroxyurea can be used to reduce WBC while awaiting confirmation</p>
</li>
<li>
<p>Oral tyrosine kinase inhibitors (TKIS): Imatinib, dasatinib,
    nilotinib, and ponatinib</p>
</li>
<li>
<p>Allogenic hematopoietic cell transplantation: Curative option for
    pts in accelerated and blast phase, as well as young pts w/chronic
    phase CML who do not respond to TKI therapy</p>
</li>
</ul>
<p>Bone Marrow Transplant – Chelsie Sievers</p>
<p>Background</p>
<ul>
<li>Donor selection</li>
</ul>
<!-- -->

<ul>
<li>
<p>Autologous: self, no matching required (no GVHD risk, but also no
    graft-vs-tumor effect)</p>
</li>
<li>
<p>Allogeneic: non-self, matching based on HLA (more matched = less
    GVHD risk)</p>
<ul>
<li>
<p>Matched-related donor (MRD): fully matched sibling</p>
</li>
<li>
<p>Matched-unrelated donor (MUD): From NMDP database</p>
</li>
<li>
<p>Haploidentical: Half matched sibling or parent</p>
</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Source of stem cells:</li>
</ul>
<!-- -->

<ul>
<li>Peripheral blood stem cells (PBSCs) vs bone marrow-derived cells vs
    umbilical cord</li>
</ul>
<!-- -->

<ul>
<li>Conditioning regimens:</li>
</ul>
<!-- -->

<ul>
<li>Myeloablative vs Reduced-intensity conditioning (RIC)</li>
</ul>
<!-- -->

<ul>
<li>GVHD prophylaxis (for allo-SCT):</li>
</ul>
<!-- -->

<ul>
<li>
<p>Regimen varies, can include tacrolimus, MMF, MTX, or thymo and
    alemtuzumab during conditioning</p>
<p>Complications/Adverse Effects:</p>
</li>
</ul>
<!-- -->

<ul>
<li>Infectious</li>
</ul>
<!-- -->

<ul>
<li>
<p>Neutropenic fever, neutropenic enterocolitis (typhlitis)</p>
</li>
<li>
<p>Bacterial infections</p>
</li>
<li>
<p>Viral infections</p>
<ul>
<li>
<p>CMV: check weekly PCR levels post-allo-SCT</p>
<ul>
<li>All CMV+ recipients are treated with letermovir
    prophylactically regardless of donor status</li>
</ul>
</li>
<li>
<p>EBV: check weekly PCR levels post allo-SCT. If EBV VL >1000 on
    two occasions, can treat with pre-emptive rituximab to reduce
    the risk of PTLD</p>
</li>
</ul>
</li>
<li>
<p>Invasive fungal infections (e.g. aspergillus, candida)</p>
</li>
</ul>
<!-- -->

<ul>
<li>Non-infectious</li>
</ul>
<!-- -->

<ul>
<li>
<p>Nausea, vomiting, diarrhea, mucositis, cytopenias</p>
</li>
<li>
<p>Hepatic veno-occlusive disease (VOD)/sinusoidal obstructive syndrome
    (SOS)</p>
<ul>
<li>
<p>Pathophysiology: sinusoidal endothelial cell damage from
    conditioning chemo post-sinusoidal portal HTN cytokine release
    multiorgan failure and death</p>
</li>
<li>
<p>Diagnosis: T Bili >2, hepatomegaly/RUQ pain, weight gain >
    2-5%</p>
</li>
<li>
<p>Evaluation: RUQ US with doppler</p>
</li>
<li>
<p>Treatment: Per heme attending; generally supportive, consider
    defibrotide</p>
</li>
</ul>
</li>
<li>
<p>Graft failure:</p>
<ul>
<li>
<p>Primary (persistent neutropenia without engraftment)</p>
</li>
<li>
<p>Secondary (delayed pancytopenia 2/2 immune phenomena or
    infection after engraftment)</p>
</li>
</ul>
</li>
<li>
<p>Engraftment syndrome:</p>
<ul>
<li>
<p>Pathophysiology: PMN recovery cytokine storm vascular leak</p>
</li>
<li>
<p>Symptoms: fever, tachycardia, hypotension, SOB, pulmonary edema,
    rash, weight gain, bone pain, confusion</p>
</li>
<li>
<p>Diagnosis: Clinical</p>
</li>
<li>
<p>Treatment: high-dose IV steroids</p>
</li>
</ul>
</li>
<li>
<p>Acute GVHD:</p>
<ul>
<li>
<p>Only in allogenic; Increased risk with more HLA mismatch</p>
</li>
<li>
<p>Pathophysiology: donor T cells attack recipient (Th1-mediated)</p>
</li>
<li>
<p>Symptoms: skin rash, cholestatic liver injury, diarrhea</p>
</li>
<li>
<p>Treatment: IV steroids (methylprednisolone 1-2mg/kg x 5d)</p>
<ul>
<li>If refractory: mycophenolate, etanercept, ruxolitinib,
    antithymocyte globulin</li>
</ul>
</li>
</ul>
</li>
<li>
<p>Chronic GVHD (typically after T+100)</p>
<ul>
<li>
<p>Can involve all organs but typically see a scleroderma-like
    picture (xerophthalmia, xerostomia dysphagia, arthritis, skin
    changes, malar rash, obliterative bronchiolitis, cholestatic
    liver injury, cytopenias)</p>
</li>
<li>
<p>Treatment: steroids (also photophoresis for skin), consider
    trials of ruxolitinib, ibrutinib, rituximab if refractory</p>
</li>
</ul>
</li>
<li>
<p>PTLD (post-transplant lymphoproliferative disorders)</p>
<ul>
<li>
<p>Pathophysiology: B-cell proliferative disease typically 2/2
    &gt; latent EBV</p>
</li>
<li>
<p>Symptoms: fever, weight loss, fatigue, lymphadenopathy,
    &gt; extra-nodal masses, ↑ EBV PCR</p>
</li>
</ul>
</li>
</ul>
<p>CAR T-cell Therapy – Chelsie Sievers</p>
<p>Background</p>
<ul>
<li>
<p>Chimeric antigen receptor T cells (CAR-T) are a type of autologous
    T-cell therapy collected from the patient and genetically modified
    to contain an extracellular tumor-specific antigen target linked to
    the internal component of the T-cell receptor.</p>
</li>
<li>
<p>Goal: patient's own T-cells can specifically target the tumor cell
    population.</p>
</li>
<li>
<p>FDA approved therapies: Kymriah (CD19), Abecema (BCMA), Breyanzi
    (CD19), Tecartus (CD19), Yescarta (CD19)</p>
</li>
</ul>
<p>Complications:</p>
<ul>
<li>
<p>Cytokine Release Syndrome</p>
<ul>
<li>
<p>Pathophysiology: Supraphysiologic immune cell response with
    release of inflammatory cytokines.</p>
<ul>
<li>
<p>Grade 1: fever ≥ 100.4, no hypotension, no hypoxia</p>
</li>
<li>
<p>Grade 2: fever ≥ 100.4, hypotension not requiring
    vasopressors and/or hypoxia requiring \&lt; 6L</p>
</li>
<li>
<p>Grade 3: fever ≥ 100.4, hypotension requiring a vasopressor,
    hypoxia requiring > 6L or non-rebreather</p>
</li>
<li>
<p>Grade 4: fever ≥ 100.4, hypotension requiring multiple
    vasopressors, hypoxia requiring positive pressure</p>
</li>
</ul>
</li>
<li>
<p>Work-up: blood and urine cultures (IV abx if needed)</p>
</li>
<li>
<p>Treatment: acetaminophen for fever, ICU transfer (grade 1 okay
    for floor), Tocilizumab 8 mg/kg IV (max 800mg; up to 3 doses in
    24 hours, 8 hours apart), Dexamethasone 10 mg IV q 6 hours
    (grade 3-4).</p>
</li>
</ul>
</li>
<li>
<p>ICANS: Immune Effector Cell-Associated Neurotoxicity Syndrome</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Pathophysiology: high systemic inflammation leaky blood brain
    barrier encephalopathy &plusmn; cerebral edema.</p>
<ul>
<li>
<p>Based on ICE score: Orientation: orientation to year, month,
    city, hospital: 4 points; Naming: ability to name 3 objects (eg,
    point to clock, pen, button): 3 points; Following commands:
    ability to follow simple commands (eg, “Show me 2 fingers” or
    “Close your eyes and stick out your tongue”): 1 point; Writing:
    ability to write a standard sentence (eg, “Our national bird is
    the bald eagle”): 1 point; Attention: ability to count backwards
    from 100 by 10: 1 point.</p>
</li>
<li>
<p>Grade 1: ICE score: 7-9</p>
</li>
<li>
<p>Grade 2: ICE score: 3-6</p>
</li>
<li>
<p>Grade 3: ICE score 0-2</p>
</li>
<li>
<p>Grade 4: ICE score 0</p>
</li>
</ul>
</li>
<li>
<p>Work-up: neuro consult, fundoscopic exam for papilledema, consider
    MRI brain w/&amp;w/o contrast, consider EEG, consider non-con CT head if
    headache/lethargy.</p>
</li>
<li>
<p>Treatment: q4hr neuro checks (q1hr if grade > 2 → ICU transfer),
    Keep Na 135-145 with hypertonic saline if necessary (Na 145-150 if
    grade 4), consider thiamine supplementation 500mg q8hrs,
    Dexamethasone 10 mg q 6 hours (if seizure give 20mg x 1, then 10mg
    q6hrs) (grade 2-3), Methylprednisolone 1000 mg IV q 24 x 3 days
    (grade 4).</p>
</li>
</ul>
<p>Oncologic Emergencies – Madeleine Turcotte</p>
<p>Leukostasis</p>
<p>Presentation</p>
<ul>
<li>
<p>Primarily occurs with acute myeloid leukemia and acute lymphoblastic
    leukemia. This is not common with CLL or CML with high leukocyte
    counts in the absence of a significant increased portion of
    peripheral blasts</p>
</li>
<li>
<p>Respiratory: dyspnea, hypoxia (note CXR may be normal)</p>
</li>
</ul>
<!-- -->

<ul>
<li>PaO2 by ABG often falsely low from WBC consuming O2 in vitro. Trust
    SpO2.</li>
</ul>
<!-- -->

<ul>
<li>CNS: headache, AMS, vision changes, dizziness, tinnitus, gait
    instability, neuro deficit</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<p>CBC with diff and peripheral blood smear</p>
</li>
<li>
<p>Imaging: CT head to evaluate neuro deficit and to check for ICH</p>
</li>
<li>
<p>Chest X-Ray vs CT chest to evaluate dyspnea and air space
    abnormalities</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>Call hematology</p>
</li>
<li>
<p>Emergent cytoreduction</p>
</li>
</ul>
<!-- -->

<ul>
<li>Leukapheresis: page nephrology and place dialysis catheter</li>
</ul>
<!-- -->

<ul>
<li>
<p>Hydroxyurea and chemotherapy per hematology fellow</p>
</li>
<li>
<p>Transfer/admit to ICU</p>
</li>
</ul>
<p>Tumor Lysis Syndrome – Bradley Christensen</p>
<p>Background</p>
<ul>
<li>
<p>Lysis of malignant cells either spontaneously or in response to
    chemotherapy causing release of K, Phos, nucleic acids, and
    cytokines</p>
</li>
<li>
<p>Consequences:</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Hyperkalemia: most urgent and immediately life threatening</p>
</li>
<li>
<p>Hyperphosphatemia: binds Ca and leads to CaPhos crystal deposition
    AKI, HypoCa</p>
</li>
<li>
<p>Hyperuricemia (from breakdown of DNA) precipitation in renal tubules
    AKI</p>
</li>
<li>
<p>Hypotension, AKI from cytokine release</p>
</li>
</ul>
<!-- -->

<ul>
<li>Laboratory TLS</li>
</ul>
<!-- -->

<ul>
<li>
<p>Uric acid ≥ 8, Ca2+ ≤ 7, K+, or PO43- ≥ 4.5</p>
</li>
<li>
<p>OR > 25% change from baseline in these values</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Risk Stratification:</li>
</ul>
<!-- -->

<ul>
<li>Highest risk after starting chemotherapy, but can occur
    spontaneously</li>
</ul>
<!-- -->

<ul>
<li>Tumor characteristics which confer a higher risk of developing TLS:</li>
</ul>
<!-- -->

<ul>
<li>
<p>High (>5% risk): ALL (WBC> 100K or LDH 2x ULN), AML (WBC> 100K),
    Burkitt’s (III/IV or LDH≥2xULN, DLBCL with bulky disease,
    intermediate risk + AKI/CKD</p>
</li>
<li>
<p>Intermediate: ALL (WBC\&lt;100K, LDH \&lt;2x ULN), AML (WBC 25-100K),
    Burkitt’s LDH\&lt;2x ULN), DLBCL (non-bulky, LDH>ULN), CLL (if tx with
    fludarabine, rituximab, lenalidomide, or venetoclax +LN 5-10 cm or
    ALC≥25K), plasma cell leukemia, rare chemo-sensitive solid tumors
    (small cell)</p>
</li>
<li>
<p>Low: all others</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>Prevention:</li>
</ul>
<!-- -->

<ul>
<li>
<p>High risk: q6-8h TLS labs, IVF (±loop diuretic if volume overload),
    allopurinol, ± rasburicase</p>
</li>
<li>
<p>Intermediate – q8h TLS labs, IVF, allopurinol</p>
</li>
<li>
<p>Low – daily TLS labs, IVF</p>
<ul>
<li>
<p>Significant hydration: goal to maintain UOP 80-100 mL/hr</p>
</li>
<li>
<p>Allopurinol: 300 mg PO BID for CrCl > 20 mL/min, UpToDate renal
    dosing if lower</p>
</li>
<li>
<p>Rasburicase ($$$): contraindicated in G6PD (send G6PD if not
    urgent and AA, Asian or Jewish descent)</p>
<ul>
<li>Given if uric acid > 8 mg/dL: get fellow approval before
    ordering</li>
</ul>
</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Treatment: (Can use as night/cross cover handoff)</li>
</ul>
<!-- -->

<ul>
<li>
<p>K+ > 5.5: STAT EKG. Kayexalate 30g orally or 60g per rectum (unless
    contraindicated) x1</p>
<ul>
<li>
<p>Give 10 U insulin/1 amp D50</p>
</li>
<li>
<p>If EKG changes, then calcium gluconate and D5W at 100 mL/hr with
    repeat BG in 1 hr</p>
</li>
</ul>
</li>
<li>
<p>Uric acid > 8 with 25% change from baseline: page hematology fellow
    to discuss rasburicase</p>
</li>
<li>
<p>PO4 > 4.5 with 25% change from baseline: start/↑ phos binder
    (sevelamer)</p>
</li>
<li>
<p>Dialysis may be necessary in patients with poor renal function.</p>
</li>
<li>
<p>IV calcium: do not administer unless symptomatic AND
    hyperphosphatemia is corrected</p>
<ul>
<li>With high phos, IV calcium can lead to calcium deposition and
    renal failure</li>
</ul>
</li>
<li>
<p>Hemodialysis: pt with anuria, refractory hyperkalemia, and
    symptomatic hypocalcemia</p>
</li>
</ul>
<p>Superior Vena Cava (SVC) Syndrome</p>
<p>Background</p>
<ul>
<li>
<p>Commonly Associated Malignancies: Lung Cancer, Non-Hodgkin or
    Hodgkin Lymphoma, Mediastinal Germ Cell Tumors, Thymic Malignancies</p>
</li>
<li>
<p>Partial or complete obstruction of the SVC impedes blood return from
    the upper extremities, head, neck, and brain resulting in upstream
    congestion</p>
</li>
<li>
<p>Can be 2/2 a mass in the mediastinum or thrombosis (foreign body
    i.e. catheter)</p>
</li>
</ul>
<p>Presentation</p>
<ul>
<li>
<p>Facial or neck swelling without generalized edema</p>
</li>
<li>
<p>Sense of head fullness, exacerbated by leaning forward or lying down</p>
</li>
<li>
<p>Pulmonary symptoms including dyspnea, stridor, hoarseness, cough -
    due to edema narrowing the nasal passages and larynx or mechanical
    airway obstruction</p>
</li>
<li>
<p>Physical Exam: facial and neck edema particularly of the eye lids in
    the morning, distended neck and chest veins; can also sometimes see
    upper extremity swelling, papilledema, plethora. Look for associated
    lymph node enlargement anywhere particularly including
    supraclavicular, cervical, and axillary region</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<p>CXR: may show mass, perihilar or mediastinal disease</p>
</li>
<li>
<p>Contrasted CT scan ± CT Venography: Phased to get a view of clot
    contribution to obstruction guides decision regarding
    anticoagulation or stenting</p>
</li>
</ul>
<!-- -->

<ul>
<li>Radiology attending can coordinate with techs (requires verbal
    direct request)</li>
</ul>
<!-- -->

<ul>
<li>MRI/MRV may provide additional information (often not possible due
    to pt too sick)</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>Assess airway and prepare for intubation if needed</p>
</li>
<li>
<p>Keep head of bed elevated</p>
</li>
<li>
<p>Thrombosis:</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Removal of lines/catheters associated with thrombus</p>
</li>
<li>
<p>Consideration of anticoagulation</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Tumor compression: the type of tumor guides treatment (tissue biopsy
    is key)</p>
</li>
<li>
<p>Stat/urgent consultations:</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Interventional radiology for possible stenting/dilatation</p>
</li>
<li>
<p>Radiation oncology- for radiation therapy</p>
</li>
<li>
<p>Interventional pulmonology – for help with tissue dx</p>
</li>
<li>
<p>Medical oncology – for help with diagnosis and chemotherapy</p>
</li>
</ul>
<p>Spinal Cord Compression</p>
<p>Background</p>
<ul>
<li>Malignancies where cord compression is most common:</li>
</ul>
<!-- -->

<ul>
<li>Multiple Myeloma, Lymphoma (both Hodgkin and NHL), Lung, Breast,
    Prostate Cancer</li>
</ul>
<!-- -->

<ul>
<li>Tumor mass &amp; compressed and often displaced bone impinges thecal sac
    or nerve roots spinal cord or any spinal nerves including the cauda
    equina</li>
</ul>
<p>Presentation</p>
<ul>
<li>
<p>Back pain, motor, or sensory deficits</p>
</li>
<li>
<p>Cauda Equina syndrome bowel or bladder incontinence, ataxia</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<p>Neurologic exam with sensation testing seeking level below an
    identified dermatome</p>
</li>
<li>
<p>Lab testing: If no known malignancy check CBC, CMP, SPEP, and (in
    males) PSA</p>
</li>
<li>
<p>Bladder US if suspicion or retention with or without overflow
    incontinence</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>If suspected, order MRI without and with contrast; if patient unable
    to have MRI, CT myelography may be considered</p>
</li>
<li>
<p>Immediate high dose steroids (dosing is controversial with
    recommendations ranging from 4 to 100 mg of dexamethasone q6h -
    choice of dexamethasone is to minimize mineralocorticoid effects.
    Most common dosing is 10mg IV x1 followed by 4mg IV q6h)</p>
</li>
<li>
<p>Consider stat/urgent consultation with:</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Neurosurgery for diagnostic/therapeutic intervention</p>
</li>
<li>
<p>Radiation oncology- for radiation therapy</p>
</li>
<li>
<p>Medical oncology – for help with diagnosis and chemotherapy</p>
</li>
</ul>
<!-- -->

<ul>
<li>Ensure regular neuro-vascular checks and close monitoring.</li>
</ul>
<p>Brain Metastases</p>
<p>Background</p>
<ul>
<li>
<p>Common malignancies: Lung (NSCLC), breast, kidney, colorectal
    carcinomas &amp; melanomas</p>
</li>
<li>
<p>Significantly more common than primary brain tumors</p>
</li>
<li>
<p>80% of brain metastasis occur in the cerebrum at grey/white matter
    junction</p>
</li>
</ul>
<p>Presentation</p>
<ul>
<li>
<p>Highly variable: consider brain mets in any cancer pt w/ neurologic
    or behavioral changes</p>
</li>
<li>
<p>Headache: worse in the mornings, with bending over or with valsalva</p>
</li>
<li>
<p>Nausea/vomiting</p>
</li>
<li>
<p>Cognitive dysfunction: changes in memory, mood or personality</p>
</li>
<li>
<p>Focal neurologic deficits</p>
</li>
<li>
<p>Signs of elevated ICP: papilledema, vision changes, drowsiness,
    presyncope</p>
</li>
<li>
<p>Seizures</p>
</li>
<li>
<p>Stroke (particularly in melanoma, choriocarcinoma, thyroid &amp; renal
    carcinomas)</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<p>STAT CT if concerned for stroke or elevated ICP</p>
</li>
<li>
<p>MRI with contrast: most sensitive, can differentiate between
    metastases vs. other lesions</p>
</li>
</ul>
<!-- -->

<ul>
<li>Suggestive features: multiple lesions, location, circumscribed
    margins, vasogenic edema</li>
</ul>
<!-- -->

<ul>
<li>
<p>If pt has no known primary tumor: consider CT C/A/P &plusmn; PET to
    identify primary</p>
</li>
<li>
<p>Biopsy with histopathology &amp; IHC: if diagnosis in doubt or if only a
    single lesion is present</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>If severe HA, N/V, focal deficits: systemic glucocorticoids</li>
</ul>
<!-- -->

<ul>
<li>Dexamethasone 10mg IV x1 followed by 4mg IV q6h (can be PO if
    tolerated)</li>
</ul>
<!-- -->

<ul>
<li>Stat/urgent consults:</li>
</ul>
<!-- -->

<ul>
<li>
<p>Neurosurgery – for diagnostic/therapeutic intervention</p>
</li>
<li>
<p>Radiation oncology – for radiation therapy</p>
</li>
<li>
<p>Medical oncology – for help with diagnosis and chemotherapy</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Ensure regular neuro-vascular checks and close monitoring</p>
</li>
<li>
<p>Do not perform LP without input from neurology</p>
</li>
</ul>
<p>Paraneoplastic Syndromes – Justin Lo</p>
<p>Hypercalcemia of malignancy</p>
<p>Background</p>
<ul>
<li>Caused by PTHrP production, osteolytic lesions, and/or rarely
    exogenous Vit D</li>
</ul>
<!-- -->

<ul>
<li>
<p>PTHrP: Breast cancer, NSCLC (squamous)</p>
</li>
<li>
<p>Osteolysis: Multiple Myeloma, Breast Cancer;</p>
</li>
<li>
<p>Exogenous Vit D: Lymphoma</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<p>Correct [Ca+2] for hypoalbuminemia: add 0.8 x (4.0 – albumin)</p>
</li>
<li>
<p>Send basic hyperCa+2 work-up – PTH, Vit D, etc. (see hypercalcemia
    section)</p>
</li>
<li>
<p>PTHrP is called “Parathyroid Hormone-related Peptide-ARUP” in Epic</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>First-line: IVF without calcium such as Normosol; goal urinary
    output of 150-200 mL/hr</li>
</ul>
<!-- -->

<ul>
<li>
<p>Strict I/Os; Cautious IV fluids if pt w/cardiac or renal dysfunction</p>
</li>
<li>
<p>Add Furosemide if hypervolemic (do not empirically start)</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Second-line: Zoledronic acid 4mg IV (takes 24-48 hours to see
    effect)</p>
</li>
<li>
<p>AMS or severe hypercalcemia (>14mg/dL): calcitonin 4 IU/kg (req.
    attending approval)</p>
</li>
</ul>
<p>SIADH</p>
<p>Background</p>
<ul>
<li>
<p>Euvolemic hypotonic hyponatremia with urine sodium >20 and
    typically urine Osm >100</p>
</li>
<li>
<p>Associated with: SCLC (most common), head/neck cancers, breast
    cancer</p>
</li>
<li>
<p>See "Nephrology" for additional information</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>Free water restriction to 800mL/day</p>
</li>
<li>
<p>Refractory: salt supplementation (e.g. salt tabs) &plusmn; loop diuretic</p>
</li>
</ul>
<p>Carcinoid Syndrome</p>
<p>Background</p>
<ul>
<li>
<p>Episodic flushing, diarrhea, wheezing/SOB due to secretion of
    histamine &amp; serotonin</p>
</li>
<li>
<p>Most common: Neuroendocrine tumors – GI (often with mets to liver
    and lung)</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<p>Urine: UR 5-HIAA (ARUP)</p>
</li>
<li>
<p>Imaging to identify tumor(s) (CT chest/abdomen/pelvis)</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>Short-term treatment: subQ or IV octreotide (see UpToDate for
    dosing)</p>
</li>
<li>
<p>Antidiarrheals (Imodium, Lomotil, etc.) to slow transit</p>
</li>
<li>
<p>Long-term treatment: depot (IM) forms of octreotide and lanreotide</p>
</li>
</ul>
<p>Autoimmune encephalitis, encephalomyelitis, and myelitis</p>
<p>Background</p>
<ul>
<li>
<p>Encephalopathy (limbic or brainstem), &plusmn; myelitis (limb ataxia,
    sensory deficits)</p>
</li>
<li>
<p>Associated with small cell lung cancer and checkpoint inhibitor
    therapy</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<p>LP: make sure to order CSF oligoclonal bands &amp; CSF IgG index</p>
</li>
<li>
<p>“Paraneoplastic AutoAb Eval-MAYO” (add "CSF" to the front of the
    order name if for LP)</p>
</li>
<li>
<p>NMDA-R can be ordered as a standalone test</p>
</li>
<li>
<p>CT head</p>
</li>
<li>
<p>EEG if concern for subclinical seizures</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>Consult Neurology, for possible immunosuppressive therapy (steroids,
    IVIG)</li>
</ul>
<p>Lambert-Eaton myasthenic syndrome (LEMS)</p>
<p>Background</p>
<ul>
<li>
<p>Muscle weakness due to autoantibody against calcium channels
    resulting in ↓ ACh release</p>
</li>
<li>
<p>Associated with SCLC (most common) &amp; lymphoma</p>
</li>
</ul>
<p>Presentation:</p>
<ul>
<li>Proximal muscle weakness, diminished DTRs</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<p>Nerve conduction studies: EMG w/ NCV</p>
</li>
<li>
<p>Serum “Paraneoplastic AutoAb Eval-MAYO”</p>
</li>
</ul>
<p>Management</p>
<p>Consult Neurology</p>
<p>Therapy Toxicities – Rahul Shah</p>
<p>Immune Checkpoint Inhibitor Toxicities:</p>
<ul>
<li>
<p>Immune checkpoint inhibitors augment the endogenous immune response
    against tumors, which may lead to autoimmune-like toxicities, known
    as immune-related adverse events (irAEs)</p>
</li>
<li>
<p>Treatment: low-dose glucocorticoids (prednisone, 0.5 mg/kg) for mild
    adverse events, high dose glucocorticoids (prednisone, 1-2 mg/kg)
    for severe adverse events</p>
</li>
</ul>
<table>
<colgroup>
<col style="width: 31%" />
<col style="width: 32%" />
<col style="width: 36%" />
</colgroup>
<thead>
<tr class="header">
<th>Adverse Event Type</th>
<th><p>Incidence with anti-CTLA-4</p>
<p>(e.g. ipilimumab)</p></th>
<th><p>Incidence with anti‐PD1/PD‐L1</p>
<p>(e.g. nivolumab, pembrolizumab)</p></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Skin (rash, pruritus, TEN)</td>
<td>30%</td>
<td>30%</td>
</tr>
<tr class="even">
<td>Colitis</td>
<td>25%</td>
<td>5%</td>
</tr>
<tr class="odd">
<td>Hypothyroidism</td>
<td>20%</td>
<td>20%</td>
</tr>
<tr class="even">
<td>Hepatitis</td>
<td>10%</td>
<td>1%</td>
</tr>
<tr class="odd">
<td>Hypophysitis</td>
<td>10%</td>
<td>rare</td>
</tr>
<tr class="even">
<td>Pneumonitis</td>
<td>2-5%</td>
<td>2-5%</td>
</tr>
<tr class="odd">
<td>Myocarditis</td>
<td>&lt;1%</td>
<td>&lt;1%</td>
</tr>
<tr class="even">
<td>Neurotoxicity (GBS, myasthenia gravis, encephalitis)</td>
<td>&lt;1%</td>
<td>&lt;1%</td>
</tr>
</tbody>
</table>

<p>Cytotoxic Agent Toxicities</p>
<table>
<thead>
<tr>
<th>Class</th>
<th>Agent</th>
<th> Side Effect</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alkylating Agents</td>
<td>Busulfan</td>
<td>Pulmonary fibrosis or diffuse alveolar hemorrhage</td>
</tr>
<tr>
<td></td>
<td>Cyclophosphamide</td>
<td>Myopericarditis, hemorrhagic cystitis (prevention: hydration; monitoring: daily UA, tx: mesna)</td>
</tr>
<tr>
<td></td>
<td>Ifosfamide</td>
<td>Encephalopathy (tx: methylene blue), nephrotoxicity, hemorrhagic cystitis</td>
</tr>
<tr>
<td>Antimetabolites</td>
<td>5- Fluorouracil (5-FU)/ Capecitabine (metabolized to FU)</td>
<td>Myelosuppression, coronary vasospasm, palmar-plantar erythrodysesthesia, mucositis</td>
</tr>
<tr>
<td></td>
<td>Cladribine, pentostatin</td>
<td>Dose reduced for CrCl</td>
</tr>
<tr>
<td></td>
<td>Cytarabine (Ara-C)</td>
<td>Irreversible cerebellar ataxia (if high dose, neuro checks required), conjunctivitis (prevent with prophylactic steroid eye drops)</td>
</tr>
<tr>
<td></td>
<td>Gemcitabine</td>
<td>Transient transaminitis, peripheral edema, rash, rarely: pulmonary toxicity, hemolytic uremic syndrome, capillary leak syndrome</td>
</tr>
<tr>
<td></td>
<td>Methotrexate</td>
<td>Stomatitis, hepatotoxicity, renal failure, high dose requires leucovorin</td>
</tr>
<tr>
<td>Antitumor antibiotics</td>
<td>Anthracyclines (doxorubicin, daunorubicin, idarubicin)</td>
<td>HFrEF (need TTE prior). Most notable with doxorubicin.</td>
</tr>
<tr>
<td></td>
<td>Bleomycin</td>
<td>Pulmonary fibrosis. Potentiated with G-CSF</td>
</tr>
<tr>
<td>Monoclonal Antibodies</td>
<td>Alemtuzumab</td>
<td>Severe and prolonged cytopenias</td>
</tr>
<tr>
<td></td>
<td>Bevacizumab</td>
<td>HFrEF, HTN, hyperglycemia, hypomag, DVT, pulm hemorrhage, GI bleeding/fistulas/perforation, wound healing complications</td>
</tr>
<tr>
<td></td>
<td>Rituximab</td>
<td>Hypophos, hepatotoxicity, HBV reactivation (screen all patients), peripheral neuropathy; transfusion reaction during 1<sup>st</sup> time infusion</td>
</tr>
<tr>
<td>Platinum Agents</td>
<td>Cisplatin, oxaliplatin, carboplatin</td>
<td>Nephrotoxicity, worst with cisplatin. Rental tubular acidosis. Neurotoxicity (parasthesias, cold sensitivity, cramps, peripheral neuropathy), ototoxicity (high frequency hearing loss), constipation, hypomag</td>
</tr>
<tr>
<td>Taxanes</td>
<td>Docetaxel, paclitaxel</td>
<td>Hypersensitivity reaction (often require premedication with steroids and H1/H2 blockers); peripheral neuropathy</td>
</tr>
<tr>
<td>Topoisomerase Inhibitors</td>
<td>Irinotecan, topotecan, etoposide</td>
<td>Irinotecan- acute diarrhea can be treated with atropine; delayed with atropine</td>
</tr>
<tr>
<td>Tyrosine Kinase Inhibitors</td>
<td>Imatinib, Dasatinib, Nilotinib, Bosutinib</td>
<td>QTc prolongation, pulmonary effusion, hepatotoxicity</td>
</tr>
<tr>
<td>Vinca alkaloid</td>
<td>Vincristine</td>
<td>Peripheral neuropathy and ototoxicity (vestibular system lost first)</td>
</tr>
</tbody>
</table>

  <hr>
<div class="md-source-file">
  <small>
    
      Last update:
      <span class="git-revision-date-localized-plugin git-revision-date-localized-plugin-iso_datetime">2022-06-09 16:32:41</span>
      
    
  </small>
</div>

              
            </article>
            
          </div>
        </div>
        
      </main>
      
        <footer class="md-footer">
  
    
    <nav class="md-footer__inner md-grid" aria-label="Footer" >
      
        
        <a href="../hematologyoncology-transfusion-medicine/" class="md-footer__link md-footer__link--prev" aria-label="Previous: Transfusion Medicine" rel="prev">
          <div class="md-footer__button md-icon">
            <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M20 11v2H8l5.5 5.5-1.42 1.42L4.16 12l7.92-7.92L13.5 5.5 8 11h12Z"/></svg>
          </div>
          <div class="md-footer__title">
            <div class="md-ellipsis">
              <span class="md-footer__direction">
                Previous
              </span>
              Transfusion Medicine
            </div>
          </div>
        </a>
      
      
        
        <a href="../../hepatology/hepatology-acute-liver-failure/" class="md-footer__link md-footer__link--next" aria-label="Next: Acute Liver Injury and Failure" rel="next">
          <div class="md-footer__title">
            <div class="md-ellipsis">
              <span class="md-footer__direction">
                Next
              </span>
              Acute Liver Injury and Failure
            </div>
          </div>
          <div class="md-footer__button md-icon">
            <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M4 11v2h12l-5.5 5.5 1.42 1.42L19.84 12l-7.92-7.92L10.5 5.5 16 11H4Z"/></svg>
          </div>
        </a>
      
    </nav>
  
  <div class="md-footer-meta md-typeset">
    <div class="md-footer-meta__inner md-grid">
      <div class="md-copyright">
  
    <div class="md-copyright__highlight">
      Copyright &copy; 2022 Vanderbilt University Medical Center <br>
Vanderbilt University Medical Center is committed to principles of equal opportunity and affirmative action. <br>
EOE/AA/Women/Minority/Vets/Disabled <br>

    </div>
  
  
    Made with
    <a href="https://squidfunk.github.io/mkdocs-material/" target="_blank" rel="noopener">
      Material for MkDocs
    </a>
  
</div>
      
    </div>
  </div>
</footer>
      
    </div>
    <div class="md-dialog" data-md-component="dialog">
      <div class="md-dialog__inner md-typeset"></div>
    </div>
    <script id="__config" type="application/json">{"base": "../..", "features": ["search.suggest", "search.highlight", "search.share"], "search": "../../assets/javascripts/workers/search.b97dbffb.min.js", "translations": {"clipboard.copied": "Copied to clipboard", "clipboard.copy": "Copy to clipboard", "search.config.lang": "en", "search.config.pipeline": "trimmer, stopWordFilter", "search.config.separator": "[\\s\\-]+", "search.placeholder": "Search", "search.result.more.one": "1 more on this page", "search.result.more.other": "# more on this page", "search.result.none": "No matching documents", "search.result.one": "1 matching document", "search.result.other": "# matching documents", "search.result.placeholder": "Type to start searching", "search.result.term.missing": "Missing", "select.version.title": "Select version"}}</script>
    
    
      <script src="../../assets/javascripts/bundle.0238f547.min.js"></script>
      
        <script src="../../js/print-site.js"></script>
      
    
  </body>
</html>